<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents</title>
				<funder ref="#_6evg9fk #_G6fRzkp">
					<orgName type="full">National Natural Science Foundation of China (NSFC</orgName>
				</funder>
				<funder>
					<orgName type="full">Zhejiang Provincial Key Discipline of Chemical Biology</orgName>
				</funder>
				<funder ref="#_g8xtP3s">
					<orgName type="full">Zhejiang Leading Innovation and Entrepreneurship Team</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2024-02-23">23 February 2024</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Feng</forename><surname>Zhang</surname></persName>
							<email>wzhang63@zjut.edu.cn</email>
							<affiliation key="aff0">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Drug Development &amp; Chemical Biology</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ruiya</forename><surname>Jiang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Drug Development &amp; Chemical Biology</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Shishi</forename><surname>Sun</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Drug Development &amp; Chemical Biology</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Caiyun</forename><surname>Wu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Drug Development &amp; Chemical Biology</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Qimeng</forename><surname>Yu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Drug Development &amp; Chemical Biology</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Annoor</forename><surname>Awadasseid</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Drug Development &amp; Chemical Biology</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Moganshan Institute</orgName>
								<orgName type="institution" key="instit2">Zhejiang University of Technology</orgName>
								<address>
									<settlement>Deqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jianwei</forename><surname>Wang</surname></persName>
							<email>wangjianwei@zjut.edu.cn</email>
							<affiliation key="aff0">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Drug Development &amp; Chemical Biology</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wen</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Drug Development &amp; Chemical Biology</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Corresponding author. College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">College of Pharmaceutical Science</orgName>
								<orgName type="institution">Zhejiang University of Technology</orgName>
								<address>
									<postCode>310014</postCode>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2024-02-23">23 February 2024</date>
						</imprint>
					</monogr>
					<idno type="MD5">64937B461AF439EAF42985FD35A5C57F</idno>
					<idno type="DOI">10.1016/j.ejmech.2024.116267</idno>
					<note type="submission">Received 7 September 2023; Received in revised form 1 February 2024; Accepted 18 February 2024</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-06-12T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>PD-L1 Degradation Post-translational modification Tumor Immunotherapy</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>PD-L1 is an important immune checkpoint protein that can bind to T cells' PD-1 receptor, thereby promoting immune escape from tumors. In recent years, many researchers have developed strategies to degrade PD-L1 to improve the effect of immunotherapy. The study of degrading PD-L1 provides new opportunities for immunotherapy. Here, we mainly summarize and review the current active molecules and mechanisms that mediate the degradation of immature and mature PD-L1 during the post-translational modification stages, involving PD-L1 phosphorylation, glycosylation, palmitoylation, ubiquitination, and the autophagy-lysosomal process. This review expects that by degrading PD-L1 protein, we will not only gain a better understanding of oncogenic mechanisms involving tumor PD-L1 protein but also provide a new way to improve immunotherapy.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>Immune checkpoints are a natural way of suppressing the immune system in the human body. Under normal physiological conditions, immune checkpoint molecules can effectively adjust the immune system and prevent excessive autoimmune diseases. But the immune escape occurs when the immune checkpoint molecules are overexpressed or overactivated, such as a cluster of differentiation 28 (CD28), programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1, CD274), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). Cancer cells can utilize immune escape to prevent the immune attack and be cleared by the immune cells, which results in the body's inability to control the growth of tumors. Among them, PD-L1 is an essential immune checkpoint protein in cancer cells that can bind to PD-1 to inhibit the proliferation and activity of T cells, causing tumor immunosuppression <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>. Therefore, restoring immunity by interrupting PD-1 and PD-L1 can increase the number of cancer cells killed by immune cells. The current popular cancer immunotherapy is to develop immune checkpoint inhibitors. Up until now, the FDA has given its approval to several monoclonal antibodies that specifically target the PD-1/PD-L1 pathway, including PD-L1 mAbs (such as Durvalumab and Atezolizumab) and PD-1 mAbs (such as Camrelizumab, Tislelizumab) <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref>. Therapy with PD-1/PD-L1 mAbs has been crucial in patient care and drug therapy across multiple cancer types <ref type="bibr" target="#b7">[8]</ref>.</p><p>In recent years, a series of biological or chemical molecules targeting the PD-1/PD-L1 interaction have been reported <ref type="bibr" target="#b8">[9]</ref>. Therein, small-molecule drug candidates that inhibit PD-1/PD-L1 have been greatly improved <ref type="bibr" target="#b9">[10]</ref>. For instance, the phenoxymethyl-biphenyl compound of Incyte Corporation (INCB86550, 1) (Fig. <ref type="figure">1</ref>) and Tianjin Chase Sun Pharmaceutical (IMMH-010, 2) (Fig. <ref type="figure">1</ref>) are undergoing different phases of clinical trials now <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</p><p>However, almost all existing drugs and candidates can only bind PD-L1 on the cell surface of cancer cells. In fact, PD-L1 can also be found in the Golgi apparatus, microvesicles, and endosomes, which can supplement and update the surface PD-L1 <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b13">14]</ref>. Both whole-cell and endogenous PD-L1 have tumor-promoting effects, which may be one of the reasons for some current drug resistance <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref>. Therefore, the complete elimination of PD-L1 on the surface and intracellularly in cancer cells should be a valid immunotherapy approach. There are currently some ways that targeting PD-L1 protein degradation or suppressing the expression of PD-L1 can restore the immune effects on tumors <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b17">18]</ref>. It can sometimes serve as a potential adjunct treatment targeting PD-1 and PD-L1. Herein, we will review the regulation of some reagents, antibodies, or drug candidates on the PD-L1 degradation of the PD-L1 protein. At the same time, we have classified the methods of degrading PD-L1 according to the degradation mode, hoping to provide another concept for targeting PD-L1 and indirectly accelerate the blossom of immunotherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">PD-L1 degradation via ubiquitin-proteasome and lysosomal pathways</head><p>There are many natural protein degradation mechanisms in cells that can degrade misfolded or unwanted proteins or organelles and recycle the released amino acids. The two major routes for protein degradation in eukaryotic cells are the ubiquitin-proteasome system (UPS) and the lysosomal degradation pathway <ref type="bibr" target="#b18">[19]</ref>. UPS is the most important protein degradation pathway with high specificity and selectivity in human cells and mainly includes two processes: ubiquitination of substrate proteins and proteasome degradation of ubiquitin-labeled proteins. Ubiquitin (Ub) is a polypeptide composed of 76 amino acids that widely exists in eukaryotic cells and can be covalently bound to substrate proteins with the help of E3 ubiquitin ligases, the tagged protein can be recognized and degraded by the 26S proteasome or prevented from degradation under the catalysis of deubiquitinase (DUB) <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b20">21]</ref>. In addition to the above, when proteins in the endoplasmic reticulum (ER) are misfolded (such as abnormal glycosylation status), they will be recognized by specific E3 enzymes and retrogradely transported to the cytoplasm, where they will be ubiquitinated and then degraded by the proteasome <ref type="bibr" target="#b21">[22]</ref>. This pathway is the ER-associated degradation (ERAD) pathway, which is also an important degradation method of UPS. While lysosome degradation, as a non-specific protein degradation pathway, is mainly based on two mechanisms: endocytosis and autophagy, which to some extent, supplement the deficiency of UPS and can participate in the degradation of extracellular protein, intact organelles, and protein polymers of surface membrane proteins <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref>. The two pathways can not only compensate for or cooperate with each other but also function independently to ensure the specific degradation of intracellular substances <ref type="bibr" target="#b24">[25]</ref>.</p><p>Targeted protein degradation technology (TPD) is a new approach that interferes with the function of proteins by utilizing the inherent degradation mechanism of regulatory proteins in eukaryotic cells. TPD provides a brand-new regulatory strategy and research tool for nonpharmaceutical targets, which greatly expands the space for new drug design and makes the treatment of intractable diseases possible <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b26">27]</ref>.</p><p>Here, using the ubiquitin-proteasome and lysosome systems to degrade PD-L1 would be a meaningful strategy. In recent years, various new targeted protein degradation technologies have emerged, including molecular glue, Proteolysis-targeting chimera (PROTAC), photoswitchable PROTAC (PhotoPROTAC), autophagy-targeting chimera (AUTAC), autophagosome-tethering compound (ATTEC),</p><p>Chaperone-mediated autophagy (CMA), and AUTOphagy-TArgeting Chimera (AUTOTAC) <ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref>. Adopting different strategies to degrade or manipulate PD-L1 protein using multiple techniques is a significant expansion of the research on the PD-1/PD-L1 axis. Many methods have been reported to degrade PD-L1, such as PROTAC-like molecules <ref type="bibr" target="#b34">[35]</ref>, lysosomal targeted chimera (LYTAC) <ref type="bibr" target="#b35">[36]</ref>, etc. These strategies allow PD-L1 proteins to be damaged by proteasomes or lysosomes, thus improving immunotherapy efficacy. In this article, we refer to these agents that target PD-L1 degradation as designed PD-L1 degraders. Correspondingly, some other PD-L1 degraders that are not specifically designed but have other functions are called multifunctional PD-L1 degraders. Among them, the designed PD-L1 degrader is mainly degraded by the lysosome, while the multifunctional PD-L1 degrader exists in both proteasome and lysosomal degradation, and some drugs even work in two degradation modes at the same time. The summary of degradation pathways helps us find new technologies for the degradation of proteins and organelles, and finds that PD-L1 degraders have good prospects in immunotherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Designed PD-L1 degraders</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">PROTAC and PROTAC-like bifunctional compounds</head><p>In 2020, Chen's group designed a series of bifunctional small molecule inhibitors by combining biphenyl compounds of BMS with the E3 ubiquitin ligase (CRBN) ligand pomalidomide <ref type="bibr" target="#b34">[35]</ref>. They found that these hybrid molecules have good inhibitory effects on the connection of human PD-1/PD-L1 with nanomole levels. Among these compounds, P22 (3) (Fig. <ref type="figure">2</ref>) not only has strong inhibitory activity (IC 50 = 39.2 nM) but can also moderately reduce PD-L1 in breast cancer cells. According to the mechanistic study, it was found that 3 degrades PD-L1 via a pathway that is dependent on lysosomes (Fig. <ref type="figure" target="#fig_0">3</ref>), which provides us with an idea of how PD-L1 can be degraded by a PROTAC-like molecule <ref type="bibr" target="#b34">[35]</ref>. In 2021, Yang et al. designed a set of small-molecule PROTACs targeting PD-L1 based on the co-crystal structure of the PD-L1 small-molecule inhibitor BMS-37 (4) (Fig. <ref type="figure">2</ref>) <ref type="bibr" target="#b36">[37]</ref>. The authors connect the ligands of E3 with the ethanediamine side chain of BMS-37 by changing the length and type of linkers. Through the WB experiment, they found that compound 21a (5) (Fig. <ref type="figure">2</ref>) has the best degradation effect on cytoplasm and membrane PD-L1 in different malignant cells. It can effectively promote the time-dependent degradation of the PD-L1 protein by relying on the proteasome (Fig. <ref type="figure" target="#fig_0">3</ref>). In vivo studies have demonstrated that compound 5 effectively promotes immune cell activity and exerts inhibitory effects on tumor growth <ref type="bibr" target="#b36">[37]</ref>. In 2022, Chen et al. combined biphenyl-like PD-L1 inhibitors and four E3 ubiquitin ligase ligands (CRBN, VHL, cIAP, and MDM2) through different linker chains to obtain 21 PD-L1 degraders <ref type="bibr" target="#b37">[38]</ref>. Degradation studies and kinetic analysis revealed that compound BMS-37-C3 (6) (Fig. <ref type="figure">2</ref>) exhibited the ability to induce time-and dose-dependent degradation of PD-L1 in A375 and B16-F10 cell lines. Both competition experiments and blocking experiments proved that 6 acts through the ubiquitin-proteasome pathway (Fig. <ref type="figure" target="#fig_0">3</ref>) and is a reliable PD-L1 degrader. In addition, 6 was found to enhance the cytotoxicity of T cells against A375 cells in a concentration-dependent manner, as demonstrated by the T cell co-culture killing assay <ref type="bibr" target="#b37">[38]</ref>.</p><p>In 2022, Fang's group developed a new integrin-facilitated lysosomal degradation (IFLD) strategy to exploit bifunctional compounds to degrade extracellular and membrane proteins <ref type="bibr" target="#b38">[39]</ref>. Integrins, which are located on the surface of cells, are crucial receptors for mediating interactions between cells and the extracellular matrix. Integrin α v β 3 is highly expressed in a variety of tumor cells, and its recognition sequence Arg-Gly-Asp (RGD) has received extensive attention in tumor therapy <ref type="bibr" target="#b39">[40]</ref>. In this study, the cyclic RGDyK (cRGD) with good stability and high hydrophilicity was selected as the integrin ligand to connect to the PD-L1 small molecule ligand, BMS-8 (7) (Fig. <ref type="figure">2</ref>), through different linkers and three compounds synthesized <ref type="bibr" target="#b38">[39]</ref>. Among these compounds, BMS-L1-RGD (8) (Fig. <ref type="figure">2</ref>) has the best degradation rate of PD-L1. While the corresponding ligands, BMS-8 and cRGD, did not lead to significant degradation of PD-L1. The study has demonstrated that this degradation is dependent on lysosomal activity rather than the proteasome (Fig. <ref type="figure" target="#fig_0">3</ref>). Finally, the compound has achieved a good anti-tumor effect and immune activation ability in vivo <ref type="bibr" target="#b38">[39]</ref>. In general, this type of bifunctional molecule has the obvious effect of using integrin to degrade PD-L1 on the membrane. It not only has the advantages of small size and non-immunogenicity but also has great application prospects for other membrane proteins (Table <ref type="table">1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">LYTAC</head><p>In 2020, Bartozzi ' s team developed a LYTAC platform that aimed at degrading extracellular and membrane-associated proteins <ref type="bibr" target="#b35">[36]</ref>. This strategy obtained great success in the degradation of apolipoprotein E4, EGFR, CD71, and PD-L1. The LYTAC can utilize lysosome-targeting receptors (LTRs)-cation-independent mannose-6-phosphate receptors (CI-M6PR) to transport membrane or extramembrane target proteins to lysosomes <ref type="bibr" target="#b40">[41]</ref>. An antibody connects it with an affinity for the target protein and a chemically synthesized mannose-6-phosphate (M6P)-modified peptide, which is an agonist of CI-M6PR. After LYTACs combine with POI and CI-M6PR to form a complex, they are transported to the lysosome with CI-M6PR for POI degradation (Fig. <ref type="figure" target="#fig_0">3</ref>) <ref type="bibr" target="#b35">[36]</ref>. The authors designed and synthesized anti-PD-L1-M6Pn LYTAC (Ab-3). In the Hodgkin lymphoma cell line HDLM-2 with obvious CI-M6PR expression, the degradation ability of Ab-3 can reach up to 50%. When HDLM-2 cells were treated with atzolizumab-derived atz-M6Pn LYTAC at a concentration of 25 nM for 48 h, PD-L1 was downregulated by 73% <ref type="bibr" target="#b35">[36]</ref> (Table <ref type="table">2</ref>). Although LYTAC still has challenges in preparation and safety, it has important development value for Fig. <ref type="figure">2</ref>. PD-L1 PROTAC molecules (3, 5, 6, 8) and its parent molecules (4, 7).</p><p>F. <ref type="bibr">Zhang et al.</ref> degrading proteins on the membrane <ref type="bibr" target="#b41">[42]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">PD-LYSO</head><p>In 2018, Xu et al. investigated the mechanism of PD-L1 lysosomal degradation using OncoBinder, an integrated approach that contains both genomic and proteomic techniques. They discovered and proved that Huntingtin-interacting protein 1-related (HIP1R) is a negative regulator of PD-L1 <ref type="bibr" target="#b42">[43]</ref>. By constructing mutant HIP1R and green fluorescent protein (GFP) fusion proteins, the authors discovered a conserved domain (771-867) of HIP1R that binds PD-L1 and a sorting sequence (966-979) that binds to lysosomes. The sorting sequence has a di-leucine sequence that not only bound to the sorting adaptor protein (AP) complex for lysosomal sorting but also interacted with ESCRT and adaptor protein ALIX for internalization to the MVB or lysosome (Fig. <ref type="figure" target="#fig_0">3</ref>) <ref type="bibr" target="#b42">[43]</ref>. Based on the above findings, the authors constructed a PD-LYSO peptide by combining the PD-L1-binding motif of HIP1R (784-807) with its lysosome sorting sequence (966-979) in pcDNA3 expression vectors. It was found that PD-LYSO could significantly degrade PD-L1 in a lysosome-dependent manner within 2.5 h (Table <ref type="table">2</ref>). This work, leveraging the specific degradation mechanism of HIP1R, holds the potential to improve the precision and effectiveness of PD-L1 degradation methods, paving the way for advancements in therapeutic development and optimization <ref type="bibr" target="#b42">[43]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">AbTAC, PROTAB, and RSPO chimera</head><p>In 2021, James A. Wells proposed recombinant bispecific antibodies (BsIgG) to degrade cell surface proteins based on PROTAC molecules (AbTAC) (Fig. <ref type="figure" target="#fig_0">3</ref>) <ref type="bibr" target="#b43">[44]</ref>. RNF43 is a transmembrane E3 ubiquitin ligase with a specific extracellular domain and an intracellular RING domain. The enzyme can ubiquitinate the target protein, thereby resulting in endocytosis and degradation of the target protein. They screened the peptides that can bind to RNF43 efficiently by phage display. Then the recombinant bispecific antibody AC-1 was constructed by using Atezolizumab as the ligand of PD-L1 and fusing it with the binding fragment of RNF43. In MDA-MB231 cells, 10 nM AC-1 could degrade 63% of the PD-L1 protein within 24 h (Table <ref type="table">2</ref>) <ref type="bibr" target="#b43">[44]</ref>. In addition, lysosomal acidification inhibitors (bafilomycin) can stop AC-1-induced degradation of PD-L1, but proteasome inhibitors (MG-132) can't. These results show that the mechanism of PD-L1 degradation by AC-1 is RNF43-and lysosomal-dependent manner <ref type="bibr" target="#b43">[44]</ref>. In addition, the research group expanded the E3 ligase, using the transmembrane ubiquitinase ZNRF3, to obtain a good PD-L1-degrading AbTAC in the next year <ref type="bibr" target="#b44">[45]</ref>. Similarly, Genentech researchers designed a bispecific antibody-based PROTAB technology that targets PD-L1 at one end and the N-terminal glycoprotein D of RNF43 or ZNRF3 at the other end, which can effectively degrade PD-L1 in SW48 xenografts (Atezo*ZNRF3-55) (Fig. <ref type="figure" target="#fig_0">3</ref>), but unlike AbTAC, its degradation pathway relies on the dual pathways of proteasome and lysosome <ref type="bibr" target="#b45">[46]</ref>. In view of the excellent ability of ZNRF3/RNF43 to degrade PD-L1, more and more researchers have </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 1</head><p>The degradation characteristics of PROTAC and PROTAC-like bifunctional compounds. PD-L1 is internalized and undergoes integrin-facilitated lysosomal degradation (IFLD). <ref type="bibr" target="#b38">[39]</ref> conducted in-depth research on these transmembrane ligases. The Niehrs' group mutated the R-spondins (RSPOs) family member RSPO2, which has the best binding interaction for ZNRF3, to obtain mutant R2FA. Subsequent mutations in the extracellular IgV-like domain of PD-1 produced PD1HAC, the unit that has a high affinity for PD-L1. Finally, R2FA binds to the PD1HAC module through a flexible glycine-serine linker to generate the bispecific RSPO2 chimera (R2PD1) <ref type="bibr" target="#b46">[47]</ref>. R2PD1 efficiently degrades overexpressed and endogenous PD-L1 in melanoma cells in a lysosome-and ZNRF3/RNF43-dependent manner. Finally, R2PD1 restored T-cell activation in a dose-dependent manner and was much more potent than Atezolizumab at the same concentration <ref type="bibr" target="#b46">[47]</ref>. The degradation efficiency of AbTAC, PROTAB, and RSPO2 chimera was relatively high, which optimizes the shortcomings of cell surface proteins that are difficult to degrade by PROTACs and provides a unique method for the degradation of novel targets. In summary, ZNRF3/RNF43 is a promising target for degrading PD-L1, which is worthy of a researcher's focus <ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">GlueTAC</head><p>In 2021, The team of Chen and Lin of Peking University reported a general technology for degrading PD-L1 on the membrane <ref type="bibr" target="#b47">[48]</ref>. An unnatural amino acid (PrUAA) is introduced into the binding region of the anti-PD-L1 nanobody (Nb-PD-L1) using a mass spectrometry screening platform (MSSP) to form the modified nanobody (GlueBody), which can covalently bind to PD-L1. To accelerate the speed of endocytosis, the GlueBody conjugates with a cell-penetrating peptide and lysosome-sorting sequence (CPP-LSS) to produce the GlueBody chimera (GlueTAC) (Fig. <ref type="figure" target="#fig_0">3</ref>). Covalent binding can avoid the problem of degradation efficiency caused by the dissociation of membrane protein degraders and membrane protein complexes in the process of endocytosis and degradation <ref type="bibr" target="#b47">[48]</ref>. Subsequent experimental results show that GlueTAC can quickly mediate endocytosis and improve PD-L1 breakdown in the lysosomes within various cancer cells, such as breast cancer, melanoma, lung cancer, and others (Table <ref type="table">2</ref>). Finally, the authors further demonstrate that GlueTAC-mediated PD-L1 degradation can activate T cells and inhibit tumor growth more efficiently and persistently than simply blocking PD-1/PD-L1 interaction in vivo <ref type="bibr" target="#b47">[48]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6.">gPD-L1-ADC</head><p>In 2018, Hung's team performed WB and flow cytometry experiments using a recombinant glycosidase (PNGase F) to prove that the connection between PD-L1 and PD-1 relies on the glycosylation of PD-L1 <ref type="bibr" target="#b48">[49]</ref>. The researchers selected 50 N-linked glycosyltransferases from The Cancer Genome Atlas (TCGA) database and used Ingenuity Pathway Analysis (IPA) and co-immunoprecipitation to find a positive correlation between the activity of B3GNT3 transferase and the glycosylation of PD-L1 in the EGF/EGFR signaling pathway within triple-negative breast cancer (TNBC). Therefore, B3GNT3 can protect PD-L1 from degradation by triggering PD-L1 glycosylation. The researchers purified the glycosylated PD-L1 (gPD-L1) antibody STM108 with high binding affinity and conjugated it with the anti-mitotic drug monomethyl auristatin E (MMAE) to form an antibody-drug conjugate (gPD-L1-ADC) (Fig. <ref type="figure" target="#fig_0">3</ref>) <ref type="bibr" target="#b48">[49]</ref>. The gPD-L1-ADC can effectively block the connection between PD-1 and PD-L1 and facilitate the internalization and degradation of PD-L1 to improve the immune activity of immune cells (Table <ref type="table">2</ref>). Moreover, it can also release residual toxins, triggering a strong side effect in adjacent breast cancer cells. The use of gPD-L1-ADC resulted in a significantly higher rate of regression (70%) on 4T1-hPD-L1 tumors compared to treatment with either MMAE or antibody alone in mice <ref type="bibr" target="#b48">[49]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7.">CDTAC</head><p>In 2023, Wang and Nie's team developed a novel nanomolecule, carbon-dot -based PROTAC (CDTAC), which can degrade PD-L1 based on carbon-dot <ref type="bibr" target="#b49">[50]</ref>. The researchers first synthesized CD with glutathione and then conducted CDTAC, which can selectively bind to PD-L1 and subsequently recruit CRBN. After a complex of CDTAC with PD-L1 forms in tumor tissue, it is moved to lysosomes by endocytosis and broken down to release CDTACs. This lets free CDTAC molecules bind to new PD-L1 proteins and CRBN in the cytoplasm, causing more PD-L1 proteins to be ubiquitinated, marked, and broken down by the proteasomal pathway (Fig. <ref type="figure" target="#fig_1">4B</ref>) <ref type="bibr" target="#b49">[50]</ref>. CDTACs have demonstrated a notable ability to degrade a considerable portion of PD-L1, with over 99% or 90% reduction observed in CT26 or B16-F10 tumor cells (Table <ref type="table">2</ref>), respectively. Fasting-mimicking diets (FMD) can further increase the Table <ref type="table">2</ref> The degradation characteristics of antibodies or peptide PD-L1 degraders. Simultaneously binds PD-L1 and CI-M6PR to form a ternary complex, resulting in the internalization of PD-L1 into lysosomes for degradation.</p><p>[36]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PD-LYSO Human colorectal cancer</head><p>The degradation rate is greater than 60% within 2.5 h.</p><p>Mimic HIP1R can bind PD-L1 to form endosomes and transport PD-L1 to lysosomes for degradation through lysosomal sorting signals.</p><p>[43]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AbTAC</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human breast cancer cells</head><p>AbTAC exhibited strong capability for promoting the degradation of PD-L1, with a DC50 of 3.4 nM and a Dmax of 63% at 24 h in MDA-MB-231 cells.</p><p>The fully recombinant bispecific antibodies simultaneously connected the transmembrane E3 ligase-RNF43 and PD-L1 on the cell surface to form a complex that was internalized into the cell, and then PD-L1 was degraded by lysosomes.</p><p>[44]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GlueTAC</head><p>Lung cancer cells, breast cancer cells, melanoma 100 nM GlueTAC induced the degradation of PD-L1, with 11% remaining in H460 cells for 12 h at 37 • C.</p><p>PrUAA mediates the covalent attachment of Gluebody to PD-L1, after which CPP induces endocytosis and LSS induces the degradation of the GlueTAC-target protein complex by the lysosome.</p><p>[48]</p><p>gPD-L1-ADC TNBC 2-10 mg/ml of gPD-L1-ADC rapidly degrades PD-L1 in BT549 cells after treatment for 2-4 min.</p><p>gPD-L1-ADC mediates PD-L1 internalization into lysosomes and degradation through the caveolaedependent endocytosis (CDE) pathway.</p><p>[49]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CDTAC</head><p>No specific cancer CDTACs degraded PD-L1 more than 99% or 90% with DC50 0.29 ± 0.06 and 0.33 ± 0.03 μM in CT26 or B16-F10 cancer cells under FMD treatment.</p><p>Extracellular CDTAC binds to PD-L1 and endocytoses into lysosomes for degradation; intracellular circulating CDTAC binds to CRBN and PD-L1 for ubiquitination and degradation.</p><p>[50]</p><p>F. Zhang et al.</p><p>activity of CDTAC. Also, CDTAC can increase the expression of phosphorylated STING and CD8 + T cells in vivo. This shows that CDTAC changes the environment around the tumor to make it less harmful. In conclusion, CDTAC has many benefits, such as the ability to break down membrane proteins, which traditional small-molecule PROTACs cannot do. This gives a new idea of how PROTAC technology could treat tumors <ref type="bibr" target="#b49">[50]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.8.">PD-L1 small-molecule inhibitors</head><p>In 2021, a bifunctional inhibitor of PD-L1-ARB-272572 (9) (Fig. <ref type="figure" target="#fig_1">4A</ref>) was developed by Chris B. Moore et al. 9 inhibited the PD-1/PD-L1 interaction with an IC 50 of 400 pM at the protein level and could induce the dimerization of PD-L1 through crystallographic studies <ref type="bibr" target="#b50">[51]</ref>. Complete loss of cell surface PD-L1 was observed in CHO-K1 cells within 1 h with the help of flow cytometry and confocal microscopy, which was mainly due to the internalization of the PD-L1 dimer on the cell surface induced by 9 (Fig. <ref type="figure" target="#fig_1">4C</ref>). In vivo experiments with humanized PD-1/PD-L1 mice implanted with MC38 cells showed that the reduction of PD-L1 is positively correlated with the anti-tumor effect. The increase in circulatory CD3 + cells and CD4 + T cells validated the mechanism of action of 9 for immunotherapy (Table <ref type="table" target="#tab_2">3</ref>) <ref type="bibr" target="#b50">[51]</ref>.</p><p>In 2021, Jiang's team reported a series of oxadiazole-containing PD-L1 inhibitors based on the biphenyl core <ref type="bibr" target="#b51">[52]</ref>. At first, they obtained hit 10 (Fig. <ref type="figure" target="#fig_1">4A</ref>) which showed a high level of inhibition in the connection between PD-1 and PD-L1 in the virtual screening assay. After docking analysis and structural optimization of 10, they find the most active 11 (Fig. <ref type="figure" target="#fig_1">4A</ref>), with inhibitory activity in the nanomolar range against the PD-1/PD-L1 connection. Furthermore, the researchers discovered that 11 exhibits the capability to trigger the dimerization, internalization, and degradation of cell-surface PD-L1 through a lysosome-dependent pathway (Fig. <ref type="figure" target="#fig_1">4C</ref>). Even more, 11 showed excellent anticancer vitality in mouse tumor models by oral administration (Table <ref type="table" target="#tab_2">3</ref>) <ref type="bibr" target="#b51">[52]</ref>. Afterward, the team designed a new PD-L1 inhibitor 12 (Fig. <ref type="figure" target="#fig_1">4A</ref>) based on 11 through the fragment coupling strategy. In addition to having good PD-1/PD-L1 inhibitory activity (IC50 = 1.8 ± 0.7 nM), 12 also shows the ability to internalize and degrade PD-L1 similar to 11 (Fig. <ref type="figure" target="#fig_1">4C</ref>) (Table <ref type="table" target="#tab_2">3</ref>) <ref type="bibr" target="#b52">[53]</ref>.</p><p>In 2022, preclinical and early clinical research conducted by Incyte revealed that INCB086550 (1) (Fig. <ref type="figure">1</ref>), the first orally administered small molecule inhibitor of PD-L1, has an IC 50 of 3.1 nM for human PD-L1 and exhibits the ability to induce PD-L1 degradation <ref type="bibr" target="#b10">[11]</ref>. The flow cytometry and confocal experimental results show that 1 competitively binds to PD-L1 mAb and rapidly induces PD-L1 dimerization and internalization and transfers to the nucleus (Fig. <ref type="figure" target="#fig_1">4C</ref>). Finally, in CD34 + humanized mice and in clinical studies, PD-L1 was degraded in a dose-dependent way after treatment with 1 and it could significantly restore the immune index (Table <ref type="table" target="#tab_2">3</ref>) <ref type="bibr" target="#b10">[11]</ref>. In the same year, Yang published a study introducing a collection of innovative biphenyl PD-L1 small molecule inhibitors, including S4-1 (13) (Fig. <ref type="figure" target="#fig_1">4A</ref>), which exhibits remarkable binding affinity and inhibitory effects on the PD-L1 protein <ref type="bibr" target="#b53">[54]</ref>. It can cause PD-L1 protein dimerization, induce protein internalization and directly reduce the amount of cell surface PD-L1 protein. Through the colocalization test, the authors also found that PD-L1 protein was transferred to the endoplasmic reticulum in large quantities, which indicated that 13 might have the ability to cause the subsequent ERAD of the PD-L1 protein (Fig. <ref type="figure" target="#fig_1">4C</ref>). Finally, 13 exhibited significant antitumor activity and improved the tumor microenvironment (Table <ref type="table" target="#tab_2">3</ref>) <ref type="bibr" target="#b53">[54]</ref>. The above findings offer a further understanding of the small-molecule inhibitors' capability to induce internalization and degradation of PD-L1, which presents a promising opportunity for the development of PD-L1 small-molecule degraders.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Multifunctional PD-L1 degraders</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.">UPS-based degraders 4.1.1. Epidermal growth factor receptor (EGFR) inhibitors</head><p>Many studies have shown that activation of EGFR leads to an increase in PD-L1 in non-small cell lung cancer (NSCLC) cells <ref type="bibr" target="#b54">[55,</ref><ref type="bibr" target="#b55">56]</ref>. In 2016, Hung's team found that the immunosuppressive ability of PD-L1 is tightly regulated by N-glycosylation <ref type="bibr" target="#b56">[57]</ref>. The glycosylated PD-L1 (gPD-L1, 45-55 KDa) is more stable than the non-glycosylated one (ngPD-L1, 33 KDa) because the latter is more likely to be degraded via E3 enzymes β-TrCP. Previous reports have shown that the expression of β-TrCP and PD-L1 is negatively correlated <ref type="bibr" target="#b57">[58]</ref>. Hung's experiments, such as immunocoprecipitation, revealed that glycogen synthase kinase 3β (GSK3β) is responsible for the phosphorylation of PD-L1, followed by binding with β-TrCP which leads to PD-L1's undergoing poly-ubiquitination and subsequent degradation (Fig. <ref type="figure" target="#fig_2">5B</ref>). By investigating the signaling pathway preceding PD-L1, the researchers discovered that the activation of EGFR can cause the inhibition of GSK3β, resulting in the stabilization of PD-L1 expression. In contrast, treatment of cells or mice with EGFR inhibitors (Gefitinib, 14, Erlotinib, 15, Lapatinib, 16, or AG1478, 17) (Fig. <ref type="figure" target="#fig_2">5A</ref>) was found to reduce PD-L1 expression and raise immune responses by promoting tumor-infiltrating cytotoxic T cells <ref type="bibr" target="#b56">[57]</ref>. Recently, there has been growing evidence that gPD-L1 is important for PD-L1-mediated tumor immunosuppression and is expected to become a target and biomarker for cancer immunotherapy <ref type="bibr" target="#b58">[59,</ref><ref type="bibr" target="#b59">60]</ref>. In 2017, Lu et al. discovered that Osimertinib (18) (Fig. <ref type="figure" target="#fig_2">5A</ref>), a third-generation EGFR-TKI, has the potential to decrease PD-L1 levels in EGFR-mutated NSCLC cells. The authors showcased that Osimertinib exhibited the ability to not only inhibit the production of PD-L1 mRNA but also degrade PD-L1 protein at the post-translational level in both NCI-H1975 and HCC827 cells. Osimertinib shortens the lifespan of PD-L1 and triggers the breakdown of PD-L1 through GSK3β-mediated degradation via the proteasome (Fig. <ref type="figure" target="#fig_2">5B</ref>) <ref type="bibr" target="#b60">[61]</ref>. In 2021, Sun et al. conducted an in-depth study of Osimertinib-induced PD-L1 degradation and found a different degradation mechanism. In rescue experiments, neither blocking β-TrCP nor inhibiting GSK3 prevented Osimertinib-induced PD-L1 reduction, whereas an E3 ubiquitin ligase membrane-associated RING-CH8 (MARCH8) did, which was not noticed before. The N-terminal region of MARCH8 interacts with PD-L1, leading to its degradation through the ubiquitin-proteasome pathway (Fig. <ref type="figure" target="#fig_3">6C</ref>). This study establishes a new linker between MARCH8 and PD-L1 modulation <ref type="bibr" target="#b61">[62]</ref>.</p><p>In 2021, Xie et al. investigated how the E3 ubiquitin ligase ARIH1 contributes to the elimination of PD-L1 and the enhancement of antitumor immunity <ref type="bibr" target="#b62">[63]</ref>. In this study, the authors screened 2125  Triggering PD-L1 dimerization and internalization, then degrading PD-L1 through lysosomes.</p><p>[52]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>12</head><p>Human breast cancer cells 12 (5 μM) induced significant degradation of PD-L1 degradation in MDA-MB-231 cells and showed good anti-tumor activity in vivo by intraperitoneal administration.</p><p>[53]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13">(S4-1) Lung and colon cancer</head><p>After 6 h of treatment with 1 μM of 13 in RKO cells, we can see the cytoplasmic increase and the decrease in the cell membrane of the PD-L1 concentration.</p><p>13 inhibits the PD1/PD-L1 axis, increases the entry of PD-L1 into the endoplasmic reticulum, and leads to subsequent ERAD.</p><p>[54]</p><p>F. Zhang et al.</p><p>FDA-approved drugs and found a third-generation EGFR inhibitor, ES-072 <ref type="bibr" target="#b18">(19)</ref> (Fig. <ref type="figure" target="#fig_2">5A</ref>) <ref type="bibr" target="#b63">[64]</ref>, which could degrade PD-L1 efficiently. The team observed that 19 induces the degradation of PD-L1 by promoting the phosphorylation of PD-L1 through the endogenous kinase GSK3α rather than the previously mentioned GSK3β-driven mechanism (Fig. <ref type="figure" target="#fig_2">5C</ref>) <ref type="bibr" target="#b56">[57]</ref>. Then, 19 was found to promote the mutual incorporation of PD-L1 with ARIH1 dose-dependently by mass spectrometry immunoprecipitation, which increases endogenous PD-L1 degradation in H1975 and HEK293T cells. Next, the authors investigated the effect of 19 combined with anti-CTLA4 therapy using a 4T1 tumor xenograft model, which resulted in a further reduction in tumor growth, or even complete regression, with total activated CD8 + cells in the tumor compared to monotherapy. The levels of toxic T cells were also significantly elevated. This is an innovative finding that EGFR inhibitors can promote anti-tumor immunity by degrading PD-L1 through ARIH1 <ref type="bibr" target="#b62">[63]</ref>.</p><p>In conclusion, the study demonstrated that EGFR-TKIs have the ability to degrade PD-L1 by affecting transcriptional and posttranslational processes in tumor cells (Table <ref type="table">4</ref>). Besides, there is much other evidence showing the inhibition or degradation of PD-L1 by inhibiting EGFR <ref type="bibr" target="#b64">[65]</ref>. However, the specific mechanism of each inhibitor is different and needs further research.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.2.">Metformin</head><p>In 2018, Hung's team found that breast cancer patients who took Metformin (20) (Fig. <ref type="figure" target="#fig_2">5A</ref>) for a long time had lower levels of PD-L1 expression in their tumor tissues <ref type="bibr" target="#b65">[66]</ref>. Extended analysis revealed that abnormal PD-L1 glycosylation occurs when S195 is phosphorylated, which blocks the translocation of PD-L1 from the endoplasmic reticulum to the Golgi. As a result, the misfolded PD-L1 is degraded through the ERAD pathway. Metformin can directly activate this phosphorylation through the activation of AMPK (Fig. <ref type="figure" target="#fig_2">5D</ref>) <ref type="bibr" target="#b65">[66]</ref>. The team identified HRD1 as an ERAD E3 ligase in charge of the degradation of PD-L1, and it is possible that HRD1 could be a target available in forthcoming cancer immunotherapy approaches. Despite this, the exact mechanism underlying HRD1's role in this pathway remains incompletely elucidated, leaving room for further exploration of its potential as a therapeutic option <ref type="bibr" target="#b65">[66]</ref>. In 2019, Liu et al. confirmed that Metformin inhibited PD-L1 by promoting the direct binding between AMPK protein and PD-L1 protein in endometrial carcinoma <ref type="bibr" target="#b66">[67]</ref>. In 2021, Yang et al. created a self-assembling nano-drug (MS NPs) by utilizing hydrogen bonds and electrostatic interactions between Metformin and the anticancer reagent 7-ethyl-10-hydroxycamptothecin (SN38, 21) (Fig. <ref type="figure" target="#fig_2">5A</ref>) <ref type="bibr" target="#b67">[68]</ref>. After the nano-drug was delivered to the tumor tissue, the chemotherapeutic drug SN38 could directly kill some cancer cells through cytotoxicity and recruit immune cells to infiltrate the tumor tissue. At the same time, Metformin could induce abnormal glycosylation and ERAD of PD-L1 to promote the killing activity of infiltrating immune cells (Fig. <ref type="figure" target="#fig_2">5D</ref>) <ref type="bibr" target="#b67">[68]</ref>. In in vivo experiments, the tumor growth of the mice in the MS NPs group was significantly inhibited, and the survival time of the mice was significantly prolonged. This study examines the mechanism by which Metformin induces the degradation of PD-L1 within the endoplasmic reticulum, offering fresh perspectives on the advancement of innovative immune checkpoint inhibitors <ref type="bibr" target="#b67">[68]</ref>.</p><p>In 2021, Ouyang et al. discovered that the electrostatic membrane association of PD-L1's cytoplasmic domain is damaged by Metformin, which can degrade PD-L1, offering a promising approach to enhance cancer immunotherapy <ref type="bibr" target="#b68">[69]</ref>. In this study, the researchers used nuclear magnetic resonance to find that the cytoplasmic domain of PD-L1 (PD-L1-CD) was bonding to the membrane in the presence of acidic phospholipids. During the process, three amino acid residues (R260, R262, and R265) of PD-L1-CD bind to acidic phospholipids on the cell membrane through electrostatic interaction <ref type="bibr" target="#b68">[69]</ref>. Moreover, palmitosylation at C272 further reinforces the membrane integration of PD-L1's cytoplasmic domain. Mutations in R260, R262, and R265 enhance the ubiquitination of PD-L1 and accelerate its degradation. Further assays found that Metformin can competitively destroy the electrostatic interaction between PD-L1's cytoplasmic domain and acidic phospholipids, thereby affecting the reaction of PD-L1-CD to cell membranes and reducing the abundance of PD-L1 <ref type="bibr" target="#b68">[69]</ref> (Fig. <ref type="figure" target="#fig_2">5E</ref>).</p><p>In summary, the above research results demonstrate a series of new mechanisms by which Metformin degrades PD-L1 on the membrane and intracellular level in different ways (Table <ref type="table">4</ref>), which provides new ideas for related immunotherapy against PD-L1. Further research on the degradation mechanism of Metformin on PD-L1 and advancing its clinical application will help to develop more effective cancer immunotherapy methods.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.3.">BMS-1166</head><p>Bristol-Myers Squibb has made significant advancements in the development of novel small-molecule immune checkpoint inhibitors that damage the connection of PD-L1 and PD-1 based on biphenyl compounds <ref type="bibr" target="#b69">[70,</ref><ref type="bibr" target="#b70">71]</ref>. These inhibitors demonstrate a remarkable ability to inhibit the PD-1/PD-L1 protein-protein interaction on the surfaces of cancer cells. Notably, one specific compound is called BMS-1166 <ref type="bibr" target="#b21">(22)</ref> (Fig. <ref type="figure" target="#fig_2">5A</ref>) has shown exceptional potency with an ultra-low IC 50 value of</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 4</head><p>The degradation characteristics of USP-based multifunctional PD-L1 degraders. Metformin can activate AMPK and phosphorylate PD-L1, causing PD-L1 to be retained in the endoplasmic reticulum and degraded through ERAD.</p><p>[66]</p><p>No specific cancer PD-L1 in RKO cells and HEK293T cells was significantly down-regulated after 24 h of Metformin at 2-8 mM.</p><p>Metformin can destroy the electronic interaction between arginine in PD-L1-CD and acidic phospholipids in the cell membrane, thereby causing PD-L1 ubiquitination and degradation.</p><p>[69]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="22">(BMS-1166) No specific cancer</head><p>When PC9/PD-L1 cells were treated with 10 μM 22 for 17 h, PD-L1 was completely converted into unglycosylated PD-L1.</p><p>Blocking PD-L1 glycosylation and retaining PD-L1 in the endoplasmic reticulum leads to ERAD.</p><p>[73]</p><formula xml:id="formula_0">23 (2- deoxyglucose)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TNBC</head><p>The cell-surface PD-L1 expression level was significantly reduced after treatment with 10 mmol/L 23 for 12 h</p><p>[77]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="24">(d-mannose) TNBC</head><p>The expression of PD-L1 decreased in a time (0-72 h) and dose (0-100 mM) dependent mannner.</p><p>[80].</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="26">(C15)</head><p>No specific cancer 26 indicated significant PD-L1 degradation at both 1 and 10 μM DMC caused an atypical buildup of PD-L1 within the endoplasmic reticulum and then degradation of PD-L1 by means of ubiquitination via RBX1.</p><p>[87]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="28">(Pyridoxal) No specific cancer</head><p>The concentration of PD-L1 in various cell lines treated with 400 μM 28 for 24 h decreased remarkably.</p><p>PD-L1 is ubiquitinated by the E3 enzyme STUB1 and degraded by the proteasome.</p><p>[88]</p><p>31 (Roscovitine) NSCLC, Breast cancer, colon cancer, and smallcell lung cancer</p><p>The abundance of PD-L1 was sharply reduced after treatment with Roscovitine (0.1 μM for A549 cells and 5 μM for Calu1 cells) for 24 h.</p><p>Roscovitine inhibits CDK5 to increase the level of FBXO22 and cause ubiquitination and degradation of PD-L1, overcoming DNA-damaging therapies resistance in cancer cells.</p><p>[89]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="32">(Dinaciclib)</head><p>Lung adenocarcinoma Dinaciclib degrades the PD-L1 protein without mRNA reduction at 5-12 nM/mL.</p><p>Ubiquitination-proteasome pathway. Ubiquitination degradation of PD-L1 by inhibiting the deubiquitinase CSN5.</p><p>[93]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>37</head><p>Human colorectal cancer PD-L1 expression is significantly reduced by 1 μM 37 for 24 h.  ABZ can induce PD-L1 ubiquitination and degradation by reducing the expression of UBQLN4.</p><p>[108]</p><p>F. Zhang et al.</p><p>1.4 nm, as determined through in vitro experiments (Table <ref type="table">4</ref>) <ref type="bibr" target="#b71">[72]</ref>. In 2020, Yu et al. found that 22 could degrade PD-1 via lysosomes in co-culture experiments. It not only abrogates glycosylation but also obstructs endoplasmic reticulum export to the Golgi of PD-L1 through WB and confocal microscopy analyses. Thereby, the accumulation of PD-L1 in the endoplasmic reticulum triggers ERAD and neutralizing its function on the surfaces of cancer cells (Table <ref type="table">4</ref>) (Fig. <ref type="figure" target="#fig_2">5D</ref>) <ref type="bibr" target="#b72">[73]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.4.">Carbohydrates</head><p>There have been studies indicating that the upregulation of PD-L1 levels in TNBC cells can be achieved through the inactivation of GSK3β by PARP inhibitors <ref type="bibr" target="#b73">[74]</ref>. To solve this problem, scientists have used PARP inhibitors that incorporate PD-L1 antibodies or synthetic PARP/PD-L1 bifunctional inhibitors to reduce PD-L1 <ref type="bibr" target="#b74">[75,</ref><ref type="bibr" target="#b75">76]</ref>. Nevertheless, the special mechanism has not been fully clarified. In 2018, Hung's team found that 2-deoxyglucose (23) (Fig. <ref type="figure" target="#fig_2">5A</ref>) could reverse PARP inhibitor-induced immunosuppression in TNBC by deglycosylation of PD-L1. They conducted experiments using WB and fluorescence-activated cell sorting (FACS) and found that 23 deglycosylated PARPi-induced PD-L1 protein and attenuated its translocation and stability in TNBC, which aggregates PD-L1 in the endoplasmic reticulum (Fig. <ref type="figure" target="#fig_2">5D</ref>) <ref type="bibr" target="#b76">[77]</ref>. However, the limited cancer cell-killing ability of 23 and the toxicity at high doses limits the use of this method. In 2020, Lim et al. combined the glycolysis inhibitor 23 with the sensitizer Gefitinib to inhibit glycosylation of PD-L1 and achieve an excellent effect in TNBC. Drawing on previous experience that combined antibody therapy can enhance 4-1BB-mediated anti-tumor effects <ref type="bibr" target="#b77">[78]</ref>, they combined the 4-1BB antibody with 23/Gefitinib synergy to further improve the efficacy of anti-tumor immunity in a TNBC mouse tumor model and achieved good results <ref type="bibr" target="#b78">[79]</ref>.</p><p>In 2022, Lv's team found that D-mannose <ref type="bibr" target="#b23">(24)</ref> (Fig. <ref type="figure" target="#fig_2">5A</ref>) at the mM level could degrade the PD-L1 protein in TNBC cells by screening the effects of various hexoses on tumor immunity <ref type="bibr" target="#b79">[80]</ref>. 24 has the ability to activate AMPK and facilitate phosphorylation of the PD-L1 protein's S195 site in mechanistic studies. This process led to reduced glycosylation of PD-L1 protein and increased subsequent proteasomal degradation (Fig. <ref type="figure" target="#fig_2">5D</ref>). Also, the results further inhibit the DNA damage repair process, which can promote the radiotherapy of tumor cells. 24 can achieve a good therapeutic effect when combined with PD-1 antibodies or radiotherapy, which significantly prolonged the survival of a mouse model of TNBC and obviously inhibited tumor growth <ref type="bibr" target="#b79">[80]</ref>.</p><p>In 2023, Huang's team designed a series of glycoside molecules utilizing the foundational structure of BMS inhibitors <ref type="bibr" target="#b80">[81]</ref>. Given that carbohydrate recognition receptors such as mannose receptor (MR) are crucial in promoting the immune response by enabling effective communication and collaboration between various immune cells, including macrophages and dendritic cells <ref type="bibr" target="#b81">[82,</ref><ref type="bibr" target="#b82">83]</ref>. A variety of saccharide derivatives were incorporated into the tail of BMS-202 <ref type="bibr" target="#b24">(25)</ref> (Fig. <ref type="figure" target="#fig_2">5A</ref>), another biphenyl molecule <ref type="bibr" target="#b83">[84]</ref>, resulting in the synthesis of a series of bifunctional glycoside compounds. In this work, they found that inhibitors C15 (26) (Fig. <ref type="figure" target="#fig_2">5A</ref>) exhibited significant PD-1/PD-L1 blockade, aroused T cells, and had anti-tumor effects in vivo, and their toxicity, permeability, and solubility were significantly improved compared to BMS molecules <ref type="bibr" target="#b80">[81]</ref>. Further research found that 26 also has the ability to decrease PD-L1 at low and high concentrations (1 and 10 μM) and reduce PD-L1 glycosylation and membrane activity. Proteomic studies of tumor tissue samples found that many trafficking proteins related to the endoplasmic reticulum were reduced, suggesting that 26 induces ERAD of PD-L1 through deglycosylation (Fig. <ref type="figure" target="#fig_2">5D</ref>) <ref type="bibr" target="#b80">[81]</ref>. Therefore, carbohydrates can regulate the PD1/PD-L1 pathway by reacting with immune cell sugar recognition receptors (Table <ref type="table">4</ref>), thereby improving the anti-tumor response, which provides a promising idea for advancing the level of immunotherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.5.">2, 5-dimethyl-celecoxib</head><p>Hepatitis B virus X (HBx) has the ability to enhance the production of microsomal prostaglandin E synthase-1 (mPGES-1) by activating the transcription factor EGR1. This consequently leads to an elevated release of prostaglandin, which can have significant implications for the immune microenvironment <ref type="bibr" target="#b84">[85]</ref>. Previous studies have shown that 2, 5-dimethyl celecoxib (DMC, 27) (Fig. <ref type="figure" target="#fig_3">6A</ref>) may control the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) <ref type="bibr" target="#b85">[86]</ref>. Nevertheless, the relationship between the immune microenvironment and HBV-related HCC caused by HBx is still unclear. In 2020, Tang et al. found that DMC may promote HBx-triggered PD-L1 ubiquitin degradation and significantly inhibit tumor growth in HCC cells overexpressing HBx <ref type="bibr" target="#b86">[87]</ref>. They found that HBx in HBV-positive HCC patients was negatively correlated with CD8 in the tumor microenvironment but positively correlated with PD-L1, CD163, and other factors. Through microarray and WB experiments, it was found that DMC enhanced AMPKα phosphorylation and binding to the PD-L1 protein, causing PD-L1 accumulation in the endoplasmic reticulum. The authors found that the E3 ubiquitin ligase RBX1 can ubiquitinate and degrade PD-L1 by protein analysis using IP-MS and si-RNA technology <ref type="bibr" target="#b86">[87]</ref> (Fig. <ref type="figure" target="#fig_3">6B</ref>). At last, DMC and Atezolizumab and their combination showed good ability in both suppressing tumor growth and decreasing the overall level of immunosuppression within the tumor microenvironment. The study on DMC offers a valuable strategic reference for addressing immunosuppression or combined immunity treatment in HBV-related cases, despite its inability to directly interact with RBX1 and degrade PD-L1 (Table <ref type="table">4</ref>) <ref type="bibr" target="#b86">[87]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.6.">STUB1 modulators</head><p>In 2021, Wang et al. selected three non-phosphorylated vitamin B6-Pyridoxal <ref type="bibr" target="#b27">(28)</ref>, Pyridoxine <ref type="bibr" target="#b28">(29)</ref>, and Pyridoxamine (30) (Fig. <ref type="figure" target="#fig_3">6A</ref>) to check the impact on PD-L1 expression level and found that 28 can effectively lower the concentration of PD-L1 in pancreatic cancer, liver cancer, and colon cancer <ref type="bibr" target="#b87">[88]</ref>. The qRT-PCR analysis and rescue experiment demonstrated that 28 promotes PD-L1 degradation in a proteasome-dependent manner. By knocking out the reported E3 ligase associated with PD-L1, the co-immunoprecipitation (co-IP) assay showed STIP1 homology, and U-box containing protein 1 (STUB1) is the E3 ligase promoting PD-L1 degradation upon 28 treatment (Table <ref type="table">4</ref>). Although the further mechanism of 28 boost PD-L1 degradation hasn't been clearly explained; targeting STUB1 with Vitamin B6 to enhance the responsiveness of tumor cells to T cells has the potential to be an option for combination immunotherapy (Fig. <ref type="figure" target="#fig_3">6C</ref>) <ref type="bibr" target="#b87">[88]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.7.">CDK5 inhibitors</head><p>In 2021, George R. Stark et al. identified Nicotinamide phosphoribosyl transferase (NAMPT) and ubiquitin E3 ligase FBXO22 as the regulators of drug resistance using the validation-based insertional mutagenesis (VBIM) method and RNA sequencing (RNA-seq) <ref type="bibr" target="#b88">[89]</ref>. They found that CDK5 could increase the PD-L1 amount in NSCLC cells, and inhibition of CDK5 with Roscovitine (31) (Fig. <ref type="figure" target="#fig_3">6A</ref>) could increase FBXO22 levels. Further research found that high expression of FBXO22 and phosphorylation of FBXO22 at S160 or S162 could advance the degradation of PD-L1 (Fig. <ref type="figure" target="#fig_3">6C</ref>). Therefore, combining Roscovitine with immune checkpoint inhibitors may enhance the vitality of DNA-damaging therapies <ref type="bibr" target="#b88">[89]</ref>. Similarly, Lu et al. also found that knocking out CDK5 can degrade PD-L1 through TRIM21 ubiquitinase, and the CDK5 inhibitor Dinaciclib (32) (Fig. <ref type="figure" target="#fig_3">6A</ref>) can significantly degrade PD-L1 at the protein level <ref type="bibr" target="#b89">[90]</ref>. Therefore, CDK5 inhibitors will be a promising PD-L1 degrader and provide an option for immunotherapy (Table <ref type="table">4</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.8.">SGLT2 inhibitors</head><p>In 2023, Yang et al. studied the effect of 98 clinical molecules on PD-L1 and found that the sodium-glucose co-transporter 2 (SGLT2) inhibitor Canagliflozin (33) (Fig. <ref type="figure" target="#fig_3">6A</ref>) perfectly reduced the expression of PD-L1 not only in several kinds of NSCLC cell lines but also in H292 xenograft mice <ref type="bibr" target="#b90">[91]</ref>. Knockout experiments exhibited that the reduction of PD-L1 initiated by Canagliflozin was a targeted effect by destroying the roles of SGLT2 and PD-L1 on the cell surface. In endocytosis-related experiments, it was found that Canagliflozin restrains the endocytic recycling of PD-L1. In subsequent studies, it was discovered that Canagliflozin facilitated the degradation of PD-L1 via SPOP ubiquitination (Fig. <ref type="figure" target="#fig_3">6C</ref>) <ref type="bibr" target="#b90">[91]</ref>. Moreover, SGLT2 was found to have a competitive effect on the communication control between PD-L1 and SPOP. Canagliflozin, alone or in combination with CTLA4 blockade, inhibits tumor growth in PBMC and CD34 + stem cells in humanized xenograft models. Evaluated the amount of SGLT2 and PD-L1 in 100 lung cancer patients and found that SGLT2 and PD-L1 were positively correlated <ref type="bibr" target="#b90">[91]</ref>. Therefore, Canagliflozin has an extremely high application value in treating NSCLC (Table <ref type="table">4</ref>). In addition, the inhibitory effect on PD-L1 expression was also observed with other SGLT2 inhibitors such as LX-4211 <ref type="bibr" target="#b33">(34)</ref> and Dapagliflozin (35) (Fig. <ref type="figure" target="#fig_3">6A</ref>), but the effect was not as good as Canagliflozin <ref type="bibr" target="#b90">[91]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.9.">CSN5 inhibitors</head><p>In the tumor microenvironment, macrophages are a highly prevalent type of immune cell known as tumor-associated macrophages (TAMs) <ref type="bibr" target="#b91">[92]</ref>. In 2016, Hung and colleagues showed that inflammation induces TAMs secretion of TNFα and activation of NFκB, which augments deubiquitinase COP9 signalosome 5 (CSN5) gene transcription and production in cancer cells <ref type="bibr" target="#b92">[93]</ref>. CSN5 decreases PD-L1 ubiquitination and increases its stability. The activity of CSN5-associated kinase can be inhibited by Curcumin (36) (Fig. <ref type="figure" target="#fig_3">6A</ref>), a natural dietary supplement <ref type="bibr" target="#b93">[94]</ref>. In this study, the authors demonstrated that 36 destabilizes PD-L1 by inhibiting the deubiquitination activity of CSN5 and sensitizes cancer cells to anti-CTLA4 antibodies, thereby facilitating anti-CTLA4 therapy <ref type="bibr" target="#b92">[93]</ref>. In 2019, Du's team reported that TAM-secreted C-C motif chemokine ligand 5 (CCL5) leads to CSN5's upregulation through the p65/STAT3 pathway and promotes the immune escape of human colorectal cancer cells <ref type="bibr" target="#b94">[95]</ref>. This is because increased expression of CSN5 results in more stable PD-L1. 37 (Fig. <ref type="figure" target="#fig_3">6A</ref>) is an inhibitor of CSN5 and binds to CSN5 with low energy (13.4 kcal/mol). CETSA experiments have confirmed the specific interaction between CSN5 and 37. In seven different colorectal cancer cell lines, 37 was found to suppress the expression of CSN5 and the synthesis of the PD-L1 protein, and in AOM/LPS mice, 37 obviously suppressed tumor growth and enhanced the cytotoxic activity of T cells <ref type="bibr" target="#b94">[95]</ref>. In 2020, Deng et al. found that the anti-inflammatory drug Berberine <ref type="bibr" target="#b37">(38)</ref> (Fig. <ref type="figure" target="#fig_3">6A</ref>) can serve as a negative moderator of PD-L1 <ref type="bibr" target="#b95">[96]</ref>. The pull-down and SPR assays demonstrated that 38 interacts with CSN5, and it was demonstrated that 38 suppressed the deubiquitination activity of CSN5 in vitro. 38 restores NSCLC cell sensitivity to T-cell cytotoxicity in vitro and limits tumor growth in Lewis tumor-bearing mice. The team revealed a new antitumor mechanism of 38 that was not known previously, indicating that 38 has the potential to be used as a small-molecule inhibitor to disrupt the immunosuppressive effects of PD-L1 <ref type="bibr" target="#b95">[96]</ref>. In 2021, a study conducted by Su revealed that the degradation of PD-L1 can be effectively triggered by Shikonin (39) (Fig. <ref type="figure" target="#fig_3">6A</ref>), which inhibits the activation of both the NF-κB/STAT3 and NF-κB/CSN5 signaling pathways. This result proves that 39 can be used as an immunotherapeutic agent and deserves further study <ref type="bibr" target="#b96">[97]</ref>. In 2023, Hu found that Docosahexaenoic acid (DHA, 40) (Fig. <ref type="figure" target="#fig_3">6A</ref>) could decrease PD-L1 expression in different types of cancer cells <ref type="bibr" target="#b97">[98]</ref>. After ruling out that DHA affects PD-L1 in gene transcription and glycosylation, they found that PD-L1 is degraded by DHA through the ubiquitin-proteasome pathway. DHA can not only inhibit CSN5 but also inhibit the palmitoylation of PD-L1 via reducing fatty acid synthase and the downstream palmitoyltransferase DHHC5, thereby controlling the expression of PD-L1. Finally, DHA enabled T-cell activation in vitro and inhibited LLC xenograft growth in vivo <ref type="bibr" target="#b97">[98]</ref>.</p><p>Overall, CSN5 inhibitors are a valuable PD-L1 degrader based on the above results (Fig. <ref type="figure" target="#fig_3">6C</ref>) (Table <ref type="table">4</ref>). Although there are still relatively few studies on inhibiting CSN5 from degrading PD-L1, further experimental and clinical studies are needed to verify its efficacy and side effects. In addition, an in-depth understanding of the role of CSN5 in other cellular signaling pathways is needed to fully evaluate its potential as a therapeutic target. However, inhibiting CSN5 to degrade PD-L1 is a promising research direction that may provide new strategies and opportunities for the development of immunotherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.10.">USP7 inhibitors</head><p>The role of USP7 as a deubiquitinating enzyme in tumors has drawn increasing attention, and many small molecules targeting USP7 have been developed <ref type="bibr" target="#b98">[99]</ref><ref type="bibr" target="#b99">[100]</ref><ref type="bibr" target="#b100">[101]</ref><ref type="bibr" target="#b101">[102]</ref>. Various tumor environments can be improved by inhibiting USP7, which is a very potent cancer therapeutic target <ref type="bibr" target="#b102">[103]</ref>. In 2020, Liu's team found that USP7 and PD-L1 were positively associated with gastric cancer samples <ref type="bibr" target="#b103">[104]</ref>. Direct interaction between USP7 and PD-L1 results in the promotion of PD-L1 deubiquitination and stabilization. Inhibition of USP7 or downregulation of its expression reduces the interaction between PD-L1 and PD-1, ultimately leading to sensitization of cancer cells to T cell toxicity in vitro and in vivo. Almac 4 (41) (Fig. <ref type="figure" target="#fig_3">6A</ref>) is a powerful and selective allosteric USP7 inhibitor <ref type="bibr" target="#b100">[101]</ref>. The authors found that PD-L1 expression decreased in a time-dependent manner in gastric cancer cells treated with 41. 41 can induce cell cycle arrest in the G2/M phase and inhibit the proliferation of gastric cancer cells in vitro and in vivo by stabilizing P53 <ref type="bibr" target="#b103">[104]</ref>. Similarly, in 2023, Xiao et al. developed a peptide called CPP-A11 <ref type="bibr" target="#b41">(42)</ref> by combining the Annexin A1 (ANXA1)-derived peptide A11 (EYVQTVKSSKG) with a cell-penetrating peptide (YGRKKRRQRRR, CPP) <ref type="bibr" target="#b104">[105]</ref><ref type="bibr" target="#b105">[106]</ref><ref type="bibr" target="#b106">[107]</ref>. 42 competitively binds to USP7 and degrades PD-L1, thus inhibiting tumor immune escape and exerting a broad-spectrum anti-tumor effect, which has an important clinical transformation value <ref type="bibr" target="#b106">[107]</ref>. Therefore, inhibiting USP7 is a promising approach to degrading PD-L1 and enhancing the sensitivity of tumor cells to immunotherapy (Fig. <ref type="figure" target="#fig_3">6C</ref>) (Table <ref type="table">4</ref>). However, further studies are currently needed to fully understand the potential efficacy and side effects of inhibiting USP7 for cancer therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.11.">Albendazole</head><p>In 2021, Liu et al. screened the anti-tumor immunity of common clinical drugs containing imidazole structures and found that Albendazole (ABZ, 43) (Fig. <ref type="figure" target="#fig_3">6A</ref>), a low-toxicity antiparasitic drug with broadspectrum activity, has the potential to regulate the immune microenvironment of tumors and significantly decrease the expression amount of PD-L1 in tumor membranes <ref type="bibr" target="#b107">[108]</ref>. In immune-competent mouse models of melanoma and lung cancer, ABZ exhibited notable potential for suppressing tumor growth and increasing the concentration and vitality of tumor-infiltrating CD8 + T cells. By inhibiting the proteasome, it was found that ABZ-induced degradation of PD-L1 was mediated by ubiquitin. In further mechanism studies, the team used a series of molecular biological methods such as immunoprecipitation-mass spectrometry and CRISPR to clarify that Ubiquilin 4 (UBQLN4), which belongs to the ubiquilin family <ref type="bibr" target="#b108">[109]</ref>, interacts with PD-L1 and stabilizes the protein level of PD-L1, while ABZ promotes ubiquitin-mediated PD-L1 degradation by downregulating UBQLN4 (Table <ref type="table">4</ref>) <ref type="bibr" target="#b107">[108]</ref>. Through bioinformatics analysis, it was found that ABZ can synergistically enhance the antitumor effect of CD73 gene deletion or CD73-specific inhibitor (APCP) in the melanoma mouse model. In summary, this study provides a predictive target for evaluating clinical immunotherapy efficacy (UBQLN4/PD-L1) and a new strategy for tumor-combined immunotherapy <ref type="bibr" target="#b107">[108]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.">Lysosome-based degraders 4.2.1. Palmitoylation inhibitor</head><p>Palmitoylation is a reversible modification of protein lipids, in which S-type palmitoylation is a covalent modification of a 16-carbon palmitoyl group to the sulfhydryl group of protein cysteine through a thioester bond. It can regulate the processes of protein transport, stability, and cell membrane binding. Palmitoylation is catalyzed by a class of palmitoyl acyltransferases containing Asp-His-His-Cys (DHHC) in the active center, so it is also called the DHHC family, which has more than 20 members in mammals <ref type="bibr" target="#b109">[110]</ref>. In 2019, Xu's group explored the influence of palmitoylation modification on PD-L1 and found that a general palmitoylation inhibitor, 2-bromopalmitic acid <ref type="bibr" target="#b43">(44)</ref> (Fig. <ref type="figure">7</ref>), could markedly reduce the palmitoylation and amount of PD-L1 in RKO cells, a type of human colorectal cancer (CRC) <ref type="bibr" target="#b110">[111]</ref>. The authors used the CSS-palm model to predict the modification site of PD-L1. They used site-directed mutagenesis combined with click chemistry to verify the existence of palmitoylation at the C272 amino acid site in the intracellular region of PD-L1. By different biochemical and cellular molecular biology experiments, the researchers found that palmitoylation effectively prevented the ubiquitination and subsequent degradation of PD-L1 in cancer cells, thus inhibiting the killing effect of T cells on tumors. Inhibiting the palmitoylation of PD-L1 can enhance its binding to endosomal sorting complexes required for transport (ESCRT). This can Fig. <ref type="figure">7</ref>. The chemical structure of 44 and its mechanism to inhibit palmitoylation and promote degradation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 5</head><p>The degradation characteristics of lysosome-based multifunctional PD-L1 degraders. 45 can activate the MITF translocation to the nucleus through the PKCα-GSK3β pathway and mediate the degradation of PD-L1 in the lysosome to exert its anti-tumor activity.</p><p>[114]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>46</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NSCLC cells</head><p>The degradation rate of PD-L1 reaches 70% with 46 (20 μM) for 48 h.</p><p>Proteasome-dependent pathway.</p><p>[115]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>47</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human breast cancer cells</head><p>The inhibitory rate of PD-L1 was 47% when cocultured with MDA-MB-231 cells at a 20 μM concentration for 24 h.</p><p>Lysosome-dependent pathway.</p><p>[</p><p>No specific cancer H460, H157, A375, and A2058 cells treated with 5 μM of TBM-1 for 24 h could significantly reduce the PD-L1 level.</p><p>TBM-1 promotes the TFEB nuclear translocation-dependent lysosomal pathway.</p><p>[117]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="49">(Amlodipine)</head><p>No specific cancer RKO cells and MDA-MB-231 cells treated with 10-20 μM of Amlodipine for 0-24 h could significantly reduce the PD-L1 level.</p><p>Amlodipine suppressed calpain binding to Beclin-1 and induced the autophagy of PD-L1 in the recycling endosome.</p><p>[118]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>52</head><p>(Lercanidipine)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary lung cancer</head><p>The expression of PD-L1 protein induced by IFNγ (10 ng/ml) was significantly reduced by treatment with Lercanidipine (2.5, 5, 10 μM) for 24 h in different primary lung cancer cells.</p><p>Lercanidipine decreases the expression of PD-L1 by suppressing calcium-dependent signaling pathways.</p><p>[120]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>53</head><p>Human lung cancer cells 53 showed 66.99% PD-L1 degradation at 20 μM for 24 h.</p><p>Lysosome-dependent pathway.</p><p>[121]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="54">(Erianin)</head><p>No specific cancer PD-L1 expression is remarkably reduced in various cancer cells treated with 10-100 μM 54 for 12 h.</p><p>Lysosome-dependent pathway. <ref type="bibr" target="#b122">[123]</ref> 55 (Sunitinib) Melanoma and NSCLC A375 treatment with Sunitinib (2.5-5 μM) for 24 h obviously reduced the expression of PD-L1 under IFN-γ exposure.</p><p>Sunitinib degrades PD-L1 by regulating p62-dependent selective autophagy. Sigma1 inhibitors trigger selective autophagy and degradation of PD-L1.</p><p>[129]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="58">(CJ2)</head><p>No specific cancer 58 displays robust global PD-L1 degradation in B16F10 cells within 24 h.</p><p>While inhibiting the synthesis of PD-L1, 58 can also degrade PD-L1 through the autophagy-lysosome system. Activates PPARγ and promotes autophagic degradation of PD-L1.</p><p>[134]</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="61">(Rigosertib) Colorectal cancer</head><p>Significantly degraded PD-L1 in a dose-and timedependent manner after treatment with 0.5-1 μM Rigosertib for 12-24 h in RKO cells.</p><p>Rigosertib induces autophagy of PD-L1 by activating the AMPK-ULK1 axis.</p><p>[138]</p><p>F. <ref type="bibr">Zhang et al.</ref> lead to PD-L1 in tumor cells being readily transported to multivesicular bodies (MVB) for lysosomal degradation (Fig. <ref type="figure">7</ref>) <ref type="bibr" target="#b110">[111]</ref>. By analyzing and validating the expression of all DHHC members in tumors and knocking down multiple DHHCs; the authors discovered that DHHC3 palmitoyltransferase plays a pivotal function in the regulation of PD-L1 palmitoylation in cancer cells. Co-localized and tissue microarray staining showed that the expression of DHHC3 was directly proportional to PD-L1 in different kinds of tumor cells. Interfering with DHHC3 expression in mouse MC38 cells led to a notable reduction in PD-L1 protein and effectively suppressed the growth of MC38 cell colonies in C57 mice. The injection of 44 in MC38 tumor-bearing mice at a dosage of 40 mg/kg resulted in powerful inhibition of PD-L1 expression, tumor growth, and an increase in the infiltration of CD8 + cells in the tumor tissue (Table <ref type="table">5</ref>) <ref type="bibr" target="#b110">[111]</ref>. These results validate the hypothesis that palmitoylation inhibitors activate antitumor immune cell activity in vivo by reducing PD-L1 expression. In addition, the authors designed a competitive inhibitor, PD-PALM, based on the polypeptide sequence near the modified site of PD-L1 by DHHC3, which can better reduce the abundance of PD-L1 in tumor cells than 44 <ref type="bibr" target="#b110">[111]</ref>. Coincidentally, Hung's group also reported similar conclusions in the same year, but they discovered that the palmitoylation modification of PD-L1 in breast cancer cells was mainly carried out by ZDHHC9 <ref type="bibr" target="#b111">[112]</ref>. Li et al. also found that knocking out ZDHHC9 in lung adenocarcinoma can inhibit PD-L1 palmitoylation and reduce its stability <ref type="bibr" target="#b112">[113]</ref>. But in general, degrading PD-L1 by small-molecule inhibition of PD-L1 palmitoylation provides a unique alternative way to improve the efficacy of  anti-PD-L1/PD-1 therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.2.">Aloperine derivatives</head><p>A novel small molecule called SA-49 (45) (Fig. <ref type="figure" target="#fig_11">8</ref>), based on Aloperine, was discovered by <ref type="bibr">Song et al., in 2019 [114]</ref>. 45 activates protein kinase Cα (PKCα) and then restrains GSK3β activity to trigger microphthalmia transcription factor (MITF) translocation to the nuclear. It can induce MITF-dependent lysosomal biogenesis and promote the degradation of PD-L1 in the lysosome (Fig. <ref type="figure" target="#fig_12">9A</ref>). Furthermore, 45 significantly improved the killing ability of T cells and NK cells, displayed favorable effects in a mouse model implanted with Lewis tumors, and showed good security <ref type="bibr" target="#b113">[114]</ref>. In 2021, this team conducted a cognitive study of Aloperine derivatives. After systematic structure-activity relationship (SAR) analysis and structural modifications, they synthesized and obtained 29 new 12N-substituted Aloperine derivatives. Among these compounds, 46 (Fig. <ref type="figure" target="#fig_11">8</ref>), known for its high activity as a PD-L1 downregulation, indicated successful degradation of both inherent and inducible PD-L1. However, the difference is that 46 induces the degradation of PD-L1 via the proteasome-dependent pathway instead of the lysosome-dependent pathway <ref type="bibr" target="#b114">[115]</ref>. In 2022, they synthesized 28 new 12N-substituted Aloperine derivatives, and the activities of degrading PD-L1 were evaluated in MDA-MB-231 cells. Among these compounds, 47 (Fig. <ref type="figure" target="#fig_11">8</ref>) has the highest activity and degrades PD-L1 through a lysosomal pathway <ref type="bibr" target="#b115">[116]</ref>. The wealth of information obtained from these findings regarding Aloperine derivatives and their potential for cancer immunotherapy makes them highly deserving of further investigation (Table <ref type="table">5</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.3.">Tubeimoside-1</head><p>In 2021, Deng et al. found Tubeimoside-1 (TBM-1, 48) (Fig. <ref type="figure" target="#fig_11">8</ref>) could effectively reduce PD-L1 levels in human lung cancer cells with low cytotoxicity among hundreds of natural compounds <ref type="bibr" target="#b116">[117]</ref>. They revealed that TBM-1 could prevent the reaction of PD-L1 and PD-1 and activate the toxicity of T cells to cancer cells by cell impedance assays and immune co-culture experiments on NSCLC and human malignant melanoma cells. TBM-1 mediates PD-L1 degradation through a lysosomal pathway that is independent of autophagosomes (Table <ref type="table">5</ref>) <ref type="bibr" target="#b116">[117]</ref>. They used small interfering RNA (siRNA) silencing and immunoblotting to establish that TBM-1 can inhibit mTORC1's activity by directly binding to mTOR and suppressing downstream substrate TFEB phosphorylation. Further investigations have revealed that the nuclear translocation of TFEB, rather than TFE3 or MITF, initiates the process of lysosome biogenesis and PD-L1 degradation (Fig. <ref type="figure" target="#fig_12">9B</ref>). In in vivo experiments, the combined use of TBM-1 and CTLA-4 antibodies can strengthen the effect of reducing the volume of LLC tumors and B16 melanoma xenografts in mice compared to the use of TBM-1 or CTLA-4 antibodies alone, which points out the direction for the practical application of TBM-1 <ref type="bibr" target="#b116">[117]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.4.">Calcium channel blockers</head><p>In 2020, Xu's team found that Amlodipine (49) (Fig. <ref type="figure" target="#fig_11">8</ref>), through a drug repurposing screening approach, has the potential to act as an inhibitor of PD-L1, enhancing the effectiveness of PD-L1-based immunotherapy <ref type="bibr" target="#b117">[118]</ref>. PD-L1 was gradually decreased by Amlodipine treatment in RKO and MDA-MB-231 cells. Rescue experiments found that lysosomal and autophagy inhibitors could weaken the Amlodipine-induced reduction of PD-L1, but the proteasome inhibitor MG132 did not affect cancer cells. By the way, the expression of autophagy markers, LC3-II, increased, and p62 decreased in the Amlodipine experimental group. These results indicate that Amlodipine induces autophagy of PD-L1 <ref type="bibr" target="#b117">[118]</ref>. To discover the relationship between Amlodipine and autophagy, the authors conducted WB and immunofluorescence assays, which revealed that inhibiting or eliminating calpain by calpeptin or siRNAs could decrease the abundance of PD-L1 and p62 and increase LC3-II <ref type="bibr" target="#b117">[118]</ref>. There is evidence that calpain can induce the cleavage of the autophagy-related protein Beclin-1 and inhibit the occurrence of autophagy <ref type="bibr" target="#b118">[119]</ref>. Here, Amlodipine induces autophagy by blocking calcium influx and reducing calpain-induced cleavage of Beclin-1. Further research found that this autophagy is highly selective for recycling endosomes and degrades the PD-L1 protein enriched in circulating endosomes (Fig. <ref type="figure" target="#fig_12">9C</ref>) <ref type="bibr" target="#b117">[118]</ref>. In the MC38 tumor-bearing mouse model, Amlodipine inhibited tumor growth in a dose-dependent manner and promoted the infiltration of CD8 + cells in tumor tissues. It is worth noting that the calcium chelator BAPTA (50) (Fig. <ref type="figure" target="#fig_11">8</ref>), as well as the other calcium channel blocker Nifedipine (51) (Fig. <ref type="figure" target="#fig_11">8</ref>), were both able to inhibit PD-L1 expression by intracellular calcium assay. In contrast, SERCA inhibitors 2,5-di-tert-butyl-1,4-benzohydroquinone (BHQ) and the sarco-endoplasmic reticulum Ca 2+ ATPase blocker drug thapsigargin could increase PD-L1 expression by increasing cytoplasmic calcium concentrations. In summary, these studies reveals a possible role for Amlodipine in blocking PD-L1 expression via a calcium-dependent pathway, which provides a new therapeutic strategy for immunotherapy <ref type="bibr" target="#b117">[118]</ref>. In 2021, Ding established that the dihydropyridine calcium channel blocker Lercanidipine (52) (Fig. <ref type="figure" target="#fig_11">8</ref>) has a different mechanism than autophagy <ref type="bibr" target="#b119">[120]</ref>. They found that Lercanidipine could suppress PD-L1 transcription by inhibiting calcium influx in NSCLC. Decreased cytosolic calcium levels inhibit downstream calmodulin kinase (CAMKII) signaling and phosphorylation of STAT1 (the transcription factor of PD-L1), resulting in reduced PD-L1 transcription and expression <ref type="bibr" target="#b119">[120]</ref>. In 2022, they modified the structure of dihydropyridine calcium channel blockers and discovered compound 53 (Fig. <ref type="figure" target="#fig_11">8</ref>), which not only greatly attenuated the side effects caused by the calcium channel blockade but also improved the ability to degrade PD-L1 <ref type="bibr" target="#b120">[121]</ref>. Further studies found that 53 degraded PD-L1 via lysosomes in a doseand time-dependent manner, and 53 showed good bioavailability and T cell-mediated tumor cell killing in mice <ref type="bibr" target="#b120">[121]</ref>. This part provides a new direction for dihydropyridine calcium channel blockers in immunotherapy (Table <ref type="table">5</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.5.">Erianin</head><p>Erianin (54) (Fig. <ref type="figure" target="#fig_13">10A</ref>) is a natural bibenzyl compound extracted from Dendrobium. Studies have shown that 54 has strong anti-colon cancer, gastric cancer, lung cancer, and bladder cancer effects <ref type="bibr" target="#b121">[122]</ref>. In 2021, Jin et al. studied the anti-tumor mechanism of 54 <ref type="bibr" target="#b122">[123]</ref>. In WB and RT-PCR experiments of HCT-116 and other cells, the decreased expression of PD-L1 mRNA and protein indicated that 54 could restrain the synthesis of PD-L1 and increase PD-L1 degradation. Further lysosome inhibition and LysoTracker Red staining experiments in HeLa cells confirmed that PD-L1 degradation was mainly due to lysosome-mediated degradation rather than proteasome degradation <ref type="bibr" target="#b122">[123]</ref>. At the gene level, 54 reduces the incorporation between HIF-1α and RAS through the mTOR/p70S6K/4EBP1 and RAS/Raf/MEK/MAPK-ERK pathways, further leading to a reduction in PD-L1 concentration (Fig. <ref type="figure" target="#fig_12">9D</ref>). In the co-culture system of T cells and HeLa cells and the mouse model of cervical cancer, 54 could significantly inhibit tumor growth and restore the cytotoxicity of T cells to kill tumor cells (Table <ref type="table">5</ref>) <ref type="bibr" target="#b122">[123]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.6.">Sunitinib</head><p>In 2021, Chen et al. found that Sunitinib (55) (Fig. <ref type="figure" target="#fig_13">10A</ref>), a multitarget receptor tyrosine kinase (RTK) inhibitor, plays a crucial role in tumor immune regulation <ref type="bibr" target="#b123">[124]</ref>. Using the Cancer Genome Atlas (TCGA), they discovered that the great majority of sunitinib targets were significantly positively associated with PD-L1 across multiple cancer types. When treating melanoma-bearing immunized mice with Sunitinib, the tumor-inhibiting effect is obvious, and the immune activity of CTL is greatly enhanced. Sunitinib-treated A375 cells' RNA-seq and gene set enrichment analysis (GSEA) found a large number of autophagy-related genes were expressed. Immunofluorescence staining and confocal microscopic analysis found that the expression of PD-L1 on the cell membrane surface was reduced, and the expression of PD-L1-p62 and PD-L1-LC3/LAMP1 colocalization increased in the cytoplasm <ref type="bibr" target="#b123">[124]</ref>. Sunitinib mediates p62 binding to PD-L1 and transfer to autolysosomes for degradation (Fig. <ref type="figure" target="#fig_13">10B</ref>). In summary, the mechanism by which Sunitinib regulates the immune activity of tumor cells is the selective autophagic degradation mediated by p62 (Table <ref type="table">5</ref>). At last, the combined use of Sunitinib and CTLA4 mAbs can greatly improve the therapeutic effect in melanoma and NSCLC patients <ref type="bibr" target="#b123">[124]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.7.">ITCH activator</head><p>MAPK-targeted therapy is an effective treatment for melanoma, but the overexpression of PD-L1/L2 on the cancer cell membrane during treatment is one of the important reasons for tumor cells to develop treatment resistance <ref type="bibr" target="#b124">[125]</ref>. In May 2022, Roger S. Lo's team found that the E3 ligase ITCH can ubiquitinate and degrade cancer surface PD-L1/L2 in engineered M229 R5, a MAPK inhibitor (MAPKi)-induced human melanoma cells, thereby enhancing T cell activation <ref type="bibr" target="#b125">[126]</ref>. The study found that ITCH can interact with and regulate PD-L1 in various tumor cells through co-immunoprecipitation and proximity labeling technology combined with mass spectrometry analysis. ITCH downregulates PD-L1 expression on the tumor cell membrane by internalizing and ubiquitinating PD-L1 to increase the lysosomal degradation of PD-L1 <ref type="bibr" target="#b125">[126]</ref>. In vitro co-culture experiments with T cells demonstrated that the level of ITCH expression in cancer cells can affect the expression of PD-L1 to regulate T cell activity. Cytometry by time of flight (CyTOF) and single-cell RNA-sequencing combined with single-cell TCR sequencing (scRNA-seq/scTCR-seq) in a murine melanoma model with MAPKi therapy showed that loss of ITCH expression in tumor cells can lead to overexpression of PD-L1, decreased infiltration of CD8 + T cells in tumors, and increased Tregs and M2-like tumor-associated macrophages (M2-like TAMs), thereby promoting tumor escape from immunosuppression and development of drug resistance. In contrast, high expression of ITCH can inhibit the upregulation of PD-L1 and maintain the proliferation and vitality of CD8 + effector T cells in the tumor. In mouse models of melanoma, colon cancer, and pancreatic cancer caused by a variety of different genotypes, the resistance to MAPKi-targeted therapy can be strongly inhibited to enhance the therapeutic effect <ref type="bibr" target="#b125">[126]</ref>. Based on the above findings, the authors propose that activation of ITCH activity could be combined with MAPKi-targeted therapy to treat cancer. According to screening the small molecule of ITCH in in vitro activity experiments, the authors found that the activator compound AK087 (56) (Fig. <ref type="figure" target="#fig_13">10A</ref>) can enhance the activity of ITCH, promote ubiquitination, and reduce the expression of PD-L1 in tumor cells (Table <ref type="table">5</ref>). In a variety of melanoma MAPK-targeted therapy mouse models, the combination of 56 and MAPKi can inhibit the development of resistance and greatly enhance the therapeutic effect. Therefore, such PD-L1-degrading therapies may have broad applications in the field of MAPKi-resistant tumors <ref type="bibr" target="#b125">[126]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.8.">Sigma1 modulators</head><p>Felix J. Kim et al. found that Sigma1 is an integral membrane scaffolding protein highly expressed in the endoplasmic reticulum of a series of cancer cells that controls the homeostasis of cellular proteins and lipids <ref type="bibr" target="#b126">[127,</ref><ref type="bibr" target="#b127">128]</ref>. In 2017, they leveraged the principle that Sigma1 can stabilize PD-L1 through glycosylation in the endoplasmic reticulum and found that Sigma1 modulators 1-(4-iodophenyl)-3-(2-adamantyl) guanidine (IPAG, 57) (Fig. <ref type="figure" target="#fig_13">10A</ref>) are capable of inducing selective autophagy in cancer cells, leading to the degradation of PD-L1 <ref type="bibr" target="#b128">[129]</ref>. They discovered that using RNAi to knock down Sigma1 or 57 could inhibit Sigma1 in TNBC cells and PC cells that were able to suppress the IFNγ-induced PD-L1. The results of this study revealed that 57 could eliminate PD-L1 and prevent PD-L1 expression at the cell membrane by selective autophagy instead of bulk macroautophagy, or ERAD (Table <ref type="table">5</ref>). Thus, Sigma1 modulators have the potential to serve as innovative drugs that regulate the tumor immune microenvironment and are helpful for PD-L1/PD-1 targeted therapy patients <ref type="bibr" target="#b128">[129]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.9.">A novel Platinum (IV) prodrug CJ2</head><p>In order to solve the problems of traditional divalent Platinum chemotherapy drugs due to their low selectivity and large side effects, Wei et al. developed a series of new Platinum (IV) prodrugs in 2023 <ref type="bibr" target="#b129">[130]</ref>. The BRD4 inhibitor JQ-1 was introduced into the axial ligand of Platinum (IV) as a functional group. Among them, CJ2 (58) (Fig. <ref type="figure" target="#fig_13">10A</ref>) demonstrated the highest efficacy in terms of therapeutic activity and showed lower levels of toxicity. 58 can simultaneously down-regulate the cell membrane and cytoplasm PD-L1 and reverses immunosuppression and improves Platinum resistance caused by DNA damage repair. They clarified that 58 not only has the characteristics that JQ-1 can inhibit the synthesis of PD-L1 at the transcriptional level <ref type="bibr" target="#b130">[131]</ref>, but also can reduce PD-L1 by accelerating degradation via the autophagy-lysosome pathway (Table <ref type="table">5</ref>). 58 can stimulate immune activity and promote the infiltration of CD8 + T cells. This reminds us that a combination of chemotherapy and PD-L1-degrading drugs can significantly prevent tumor growth by deregulating the immunosuppressive microenvironment and enhancing DNA damage <ref type="bibr" target="#b129">[130]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.10.">PPARγ modulators</head><p>Peroxisome proliferator-activated receptor γ (PPARγ), a member of the nuclear hormone receptor superfamily, is a transcription factor that regulates gene expression. PPARγ is involved in a variety of physiological processes, including adipocyte differentiation, glucose metabolism, and inflammation. It is also the target of several drugs used to treat type 2 diabetes and related metabolic disorders. It mainly includes three subtypes of PPARα, PPARβ/δ, and PPARγ. Among them, the PPARγ subtype has attracted the most attention from scholars, and PPARγ plays a crucial role in regulating cellular metabolism, inflammation, immunity, and cancer progression <ref type="bibr" target="#b131">[132]</ref>. In 2023, Hou's team found that the expression of PPARγ can promote the activation of T cells in NSCLC to relieve immunosuppression, which is related to the decrease in PD-L1 protein level through clinical analysis <ref type="bibr" target="#b132">[133]</ref>. Further analysis revealed that PPARγ contains the LC3 interacting region motif, which can associate with LC3 in autophagosomes, leading to the degradation of PD-L1 in lysosomes <ref type="bibr" target="#b132">[133]</ref>. They found that the PPARγ agonist Pioglitazone (59) (Fig. <ref type="figure" target="#fig_13">10A</ref>) could induce autophagic degradation of PD-L1 in a PPARγ-dependent manner without affecting its gene expression (Table <ref type="table">5</ref>) <ref type="bibr" target="#b133">[134]</ref>. By immunofluorescence analysis, Pioglitazone promoted the binding of PD-L1 to PPARγ and its translocation to lysosomes. In addition, combined Pioglitazone and PD-1 antibodies increase CD8 + T cells and enhance colorectal tumor immunotherapy <ref type="bibr" target="#b133">[134]</ref>. However, current research on the relationship between PPARγ and PD-L1 has many contradictory views, such as PPARγ antagonist GW9662 (60) (Fig. <ref type="figure" target="#fig_13">10A</ref>) inhibits adipogenesis, which can reduce the expression of PD-L1 <ref type="bibr" target="#b134">[135]</ref>, or that thiazolidinedione agonists increase the expression of PD-L1 in MSS + colorectal cancer cells <ref type="bibr" target="#b135">[136]</ref>. Regardless of the inhibition or activation of PPARγ, all studies point to the positive significance of this target for the combination of PD-1/PD-L1 antibodies on immunity <ref type="bibr" target="#b133">[134]</ref><ref type="bibr" target="#b134">[135]</ref><ref type="bibr" target="#b135">[136]</ref><ref type="bibr" target="#b136">[137]</ref>. The reasons for the conflicting conclusions may be attributed to differences in cell types, different drug selections between PPAR subtypes, ambiguous properties of drugs between antagonists and agonists, or even the paradoxical role of PPARγ in cancer progression <ref type="bibr" target="#b132">[133]</ref>. Further research is required to fully understand the involvement of PPARγ in immune function.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.11.">Rigosertib</head><p>In 2023, Xiao et al. observed in experiments that Rigosertib (61) (Fig. <ref type="figure" target="#fig_13">10A</ref>) can effectively reshape the tumor immune microenvironment, and its anti-tumor effect on BALB/c mice with normal immune function is significantly better than that on nude mice <ref type="bibr" target="#b137">[138]</ref>. Decreased PD-L1 was observed in Rigosertib-treated colon cancer tumors and cells in a time-and concentration-dependent manner in vivo and in vitro. Both the lysosomal inhibition assay and immunofluorescence proved the degradation of PD-L1 via the lysosomal pathway. Transmission electron microscopy and immunofluorescence staining observed the appearance of autophagic vacuoles and LC3-II during Rigosertib-induced autophagic degradation of PD-L1 (Table <ref type="table">5</ref>) <ref type="bibr" target="#b137">[138]</ref>. Mechanistically, the AMP-activated protein kinase UNC-51-like kinase 1 (AMPK-ULK1) axis plays a key role in Rigosertib-induced autophagy (Fig. <ref type="figure" target="#fig_13">10C</ref>). Further research found that the combination of Rigosertib and CTLA-4 blockade effectively suppressed tumor growth in the CRC isograft model. Altogether, Rigosertib is expected to become a PD-L1 degradation drug for immunotherapy of colorectal cancer <ref type="bibr" target="#b137">[138]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Summary and Outlook</head><p>PD-L1 is a key immunoregulatory protein that is expressed on the surface of many tumor cells and can suppress the immune system's response by connecting to PD-1 on T cells, thereby helping tumor cells escape immune surveillance. Degrading PD-L1 has become a research hotspot in the treatment of tumors. More and more evidence has shown that inhibiting PD-L1 expression or improving PD-L1 protein degradation can effectively promote cancer immunotherapy <ref type="bibr" target="#b138">[139]</ref><ref type="bibr" target="#b139">[140]</ref><ref type="bibr" target="#b140">[141]</ref>. In addition to the methods mentioned in the article to degrade PD-L1 during PTM, many other methods of degrading or reducing PD-L1 have not been mentioned in this article due to space limitations. For example, 6-diazo-5-oxo-L-norleucine (DON, GFAT1 inhibitors) can inhibit glycosylation and degrade PD-L1 <ref type="bibr" target="#b141">[142]</ref>. Sulforaphane can not only inhibit the expression of PD-1 in CAR-T cells but also increase β-TrCP, thereby inducing the ubiquitination and degradation of PD-L1 <ref type="bibr" target="#b142">[143]</ref>. There are also a large number of protein kinases and DNA regulators (such as STAT3 <ref type="bibr" target="#b16">[17]</ref>, AKT <ref type="bibr" target="#b17">[18]</ref>, mTOR <ref type="bibr" target="#b57">[58]</ref>, BET <ref type="bibr" target="#b130">[131]</ref>, NFκB <ref type="bibr" target="#b143">[144,</ref><ref type="bibr" target="#b144">145]</ref>, NR4A1 <ref type="bibr" target="#b145">[146]</ref>, ISG15 <ref type="bibr" target="#b146">[147]</ref>) that can reduce expression or degrade PD-L1 by affecting downstream pathways.</p><p>Although this article summarizes the benefits of degrading PD-L1 in tumors, many difficulties and challenges exist in studying PD-L1 degraders. Since most drugs do not specifically target PD-L1 and need to reach a higher concentration to achieve a better degradation effect, this is likely to cause toxic effects and side effects targeting other targets. It is meaningful to study drugs that specifically degrade PD-L1. In addition, many studies still need to define the mechanism of PD-L1 degradation. For example, Osimertinib <ref type="bibr" target="#b60">[61,</ref><ref type="bibr" target="#b61">62]</ref> and Metformin <ref type="bibr" target="#b65">[66,</ref><ref type="bibr" target="#b68">69]</ref> exert degradation effects through multiple pathways; determining their correlation is a topic worthy of study. The relationship between the specific mechanism of certain drugs in reducing PD-L1 and the signaling pathway is not certain, and there are even large differences in related studies. Although many PROTAC methods for degrading proteins have been reported in terms of drug design, it is still difficult to develop small degrading molecules for the PD-L1 protein on the membrane. At present, the development of new antibody or peptide degraders such as LYTAC <ref type="bibr" target="#b35">[36]</ref>, AbTAC <ref type="bibr" target="#b43">[44]</ref>, GlueTAC <ref type="bibr" target="#b47">[48]</ref>, PD-LYSO <ref type="bibr" target="#b42">[43]</ref>, and gPD-L1-ADC <ref type="bibr" target="#b48">[49]</ref> and the change in pharmaceutical preparations such as CDTAC <ref type="bibr" target="#b49">[50]</ref>, polymer <ref type="bibr" target="#b147">[148,</ref><ref type="bibr" target="#b148">149]</ref>, self-assembling peptides <ref type="bibr" target="#b149">[150]</ref> have achieved good results. However, these technologies require drug developers to have a certain knowledge of biological and drug delivery systems, and the safety, selectivity, and drug clearance rates need further exploration <ref type="bibr" target="#b41">[42]</ref>.</p><p>In order to develop more small molecules that can specifically degrade PD-L1, the following aspects can be explored: It is feasible to obtain compounds that can degrade PD-L1 from old drugs or combine these drugs with immune stimulators to solve the shortcomings of existing drugs, such as Metformin, Canagliflozin, Amlodipine, and EGFR inhibitors. In addition, it is also feasible to find drugs that reduce PD-L1 from some natural products such as Dendrobium and Triptolide <ref type="bibr" target="#b122">[123,</ref><ref type="bibr" target="#b150">151]</ref>. Exploit proteins or signaling pathways that can be involved in PD-L1, such as inhibiting the protein CMTM4/6 that maintains PD-L1 stability <ref type="bibr" target="#b151">[152,</ref><ref type="bibr" target="#b152">153]</ref>, using the REIC/DKK-3 protein to destroy the roles of CMTM6 and PD-L1 <ref type="bibr" target="#b153">[154]</ref>, or activating the AMPK pathway <ref type="bibr" target="#b154">[155]</ref>, or activating the negative regulatory protein zymogen granule protein 16 (ZG16) of PD-L1 <ref type="bibr" target="#b155">[156]</ref>, may reduce the stability of PD-L1 and lead to its degradation. Harnessing the potential of newly identified E3 enzymes, particularly those cell membrane E3 ligases like ZNRF3/RNF43 or deubiquitinases that are specific for degrading PD-L1, offers a promising pathway for the development of corresponding PROTACs or inhibitors. These designed molecules aim to amplify the degradation of the PD-L1 protein, providing a novel approach to enhance immunotherapy efficacy by targeting and modulating immune checkpoint functions <ref type="bibr" target="#b156">[157,</ref><ref type="bibr" target="#b157">158]</ref>. The role of ubiquitinases or deubiquitinases, such as USP22 and CSN5, in the ubiquitination regulation of PD-L1 is also worth exploring <ref type="bibr" target="#b158">[159]</ref>. The development of inhibitors or PROTACs related to PD-L1 glycosylation or palmitoylation is a promising direction for PD-L1 degradation, such as peptide-PROTACs targeting PD-L1 palmitoyltransferase ZDHHC3 (DHHC3), rather than directly targeting PD-L1 <ref type="bibr" target="#b159">[160]</ref>. It is of great value to develop more small molecules that induce the internalization of PD-L1 and degradation using the autophagy-lysosome pathway <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b50">51,</ref><ref type="bibr" target="#b51">52,</ref><ref type="bibr" target="#b53">54]</ref>. This type of molecule can inhibit and degrade PD-L1 to exert a dual immune effect and has a good development prospect.</p><p>Overall, this research direction provides a potential strategy for improving the tumor immune microenvironment and immunotherapy. PD-L1 degraders, as an emerging immunotherapy strategy, have potential therapeutic advantages and prospects <ref type="bibr" target="#b160">[161]</ref>. However, these drugs still need further research and development to improve their specificity, efficacy, and safety. At the same time, individualized treatment should be carried out according to the patient's specific situation, including factors such as tumor types, PD-L1 expression level, and immune status. In the future, with the continuous advancement of technology and the deepening of research, it is believed that PD-L1-degrading agents will become an important way of treating tumors, bringing better therapeutic effects and quality of life to patients. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CRediT authorship contribution statement</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Declaration of Competing Interest</head><p>The work described has not been submitted elsewhere for publication, in whole or in part, and it is not being submitted to any other journal. All the authors listed have reviewed the final version of the manuscript and approve it for publication.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 3 .</head><label>3</label><figDesc>Fig. 3. Various technologies to degrade PD-L1 have similar degradation principles, including PROTACs (3, 5, 6, 8), LYTAC, PD-LYSO, AbTAC, PROTAB, GlueTAC, and gPD-L1-ADC.</figDesc><graphic coords="4,126.99,55.44,341.28,221.62" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 4 .</head><label>4</label><figDesc>Fig. 4. (A) PD-L1 small-molecule inhibitors (9, 11-13) that degrade PD-L1 and the original molecule of 11 (10). (B) Mechanism of CDTAC degradation of PD-L1. (C) Mechanism of PD-L1 small-molecule inhibitors (1, 9, 11-13) for degrading PD-L1.</figDesc><graphic coords="6,126.94,55.42,341.42,259.06" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 5 .</head><label>5</label><figDesc>Fig. 5. (A) Chemical structures of 14-26. (B) EGFR inhibitor-mediated degradation of non-glycosylated PD-L1. (C) 19 destabilizes PD-L1 via the E3 ligase ARIH1. (D) Metformin (20) and carbohydrates small molecules (22-24, 26) induce ERAD of PD-L1. (E) Metformin (20) disrupts the electrostatic membrane association of the PD-L1 cytoplasmic domain, leading to its degradation.</figDesc><graphic coords="7,126.99,438.86,341.28,268.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 6 .</head><label>6</label><figDesc>Fig. 6. (A) Chemical structures of 27-41 and Albendazole (43). (B) DMC (27) destabilizes PD-L1 via the E3 ligase RBX1. (C) Degradation of PD-L1 by regulation of ubiquitinase and deubiquitinases.</figDesc><graphic coords="8,126.99,55.41,341.28,277.78" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc>the concentration of PD-L1 induced by HBx in HCC cells in a time-and dose-dependent pathway (24 h and 10 μM).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head></head><label></label><figDesc>of Canagliflozin remarkably reduced the abundance of PD-L1 in various cell lines for 24 h Canagliflozin disrupts the colocalization of SGLT2 and PD-L1 and induces PD-L1 endocytosis and SPOP-mediated ubiquitin-proteasomal degradation.[91] 36 (Curcumin) Breast, colon, lung cancers, and melanoma PD-L1 expression is significantly reduced in different cancer cells treated with 50-100 μM 36.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>5 5</head><label>55</label><figDesc>μM of 39 showed a lower expression of PD-L1 in PC cells. 39 can prevent the NF-κB/STAT3 and NF-κB/CSN5 signaling pathways to promote PD-L1 degradation. μM of DHA significantly decreased the amount of PD-L1 in various cell lines for 24 h. By inhibiting CSN5 and the palmitoyltransferase DHHC5, DHA facilitates the degradation of PD-L1 via the ubiquitin-μM of 41 showed a dramatically reduced level of PD-L1 in 48-120 h, especially in human gastric cancer cells. Increase ubiquitination and degradation of PD-L1 via inhibiting USP7.[104] 42 (CPP-A11) Melanoma, lung cancer, and breast cancer cells 42 dramatically reduced PD-L1 expression when incubated with 10 μM for 24 h.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head></head><label></label><figDesc>cancer ABZ can significantly reduce the protein level of PD-L1 induced by IFN-γ in melanoma and lung cancer cells at a concentration of 0.625-1.25 μM for 24 h.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head></head><label></label><figDesc>cells were incubated with 50 μM 44 for 24 h can significantly degrade PD-L1. 44 inhibits palmitoylation of PD-L1 by interfering with palmitoyltransferase DHHC3, thereby promoting the ubiquitination modification of PD-L1, leading to the transport and degradation of PD-L1 to late endosomes and lysosomes.[111] 45 (SA-49) NSCLC cells 10-20 μM of 45 significantly reduced the PD-L1 amount in NSCLC cells at 24 h.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head></head><label></label><figDesc>reduce tumor cell surface and total PD-L1/L2 levels at 20-80 μM for 6 days. Activation of the E3 enzyme ITCH to induce ubiquitindirected lysosomal degradation of PD-L1. -231 and PC3 cells were treated with 57 (20 μM) for 16 h, dramatically reducing the concentration of cell membrane PD-L1.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head></head><label></label><figDesc>Pioglitazone can degrade about 50% of PD-L1 in 12 h.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Fig. 8 .</head><label>8</label><figDesc>Fig. 8. Chemical structures of Aloperine derivatives (45-47), TBM-1 (48), and different calcium channel blockers (49-53).</figDesc><graphic coords="13,77.39,55.42,440.50,185.47" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head>Fig. 9 .</head><label>9</label><figDesc>Fig. 9. (A) Mechanism of 45-induced degradation of PD-L1. (B) Mechanism of TBM-1 (48) induced degradation of PD-L1. (C) Mechanism of Amlodipine (49) induced degradation of PD-L1. (D) Mechanism of 54 induced degradation of PD-L1.</figDesc><graphic coords="13,126.99,279.55,341.28,286.13" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head>Fig. 10 .</head><label>10</label><figDesc>Fig. 10. (A) Chemical structures of 54-61. (B) Sunitinib (55) induces PD-L1 degradation through autophagy. (C) Rigosertib (61) induces PD-L1 degradation through autophagy.</figDesc><graphic coords="14,77.33,382.58,440.64,334.08" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_14"><head>Feng Zhang :</head><label>Zhang</label><figDesc>Writingreview &amp; editing, Writingoriginal draft, Visualization, Validation, Software, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Ruiya Jiang: Visualization, Validation, Software, Methodology, Investigation, Formal analysis, Data curation. Shishi Sun: Validation, Methodology, Investigation. Caiyun Wu: Validation, Methodology, Investigation, Data curation. Qimeng Yu: Validation, Methodology, Investigation, Formal analysis, Data curation. Annoor Awadasseid: Writingreview &amp; editing, Writingoriginal draft, Visualization, Validation, Investigation. Jianwei Wang: Visualization, Validation, Investigation, Conceptualization. Wen Zhang: Writingreview &amp; editing, Visualization, Validation, Supervision, Resources, Project administration, Investigation, Funding acquisition, Conceptualization.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc></figDesc><graphic coords="3,127.05,575.56,341.14,150.62" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>The degradation characteristics of PD-L1 small-molecule inhibitors.</figDesc><table><row><cell>Agents</cell><cell>Cancer Types/cancer</cell><cell>Degradability/Biological evaluation</cell><cell>Mechanisms of degrade PD-L1</cell><cell>Reference</cell></row><row><cell></cell><cell>cell lines</cell><cell></cell><cell></cell><cell></cell></row><row><cell>1 (INCB086550)</cell><cell>Human breast cancer</cell><cell>1 μM of 1 effectively reduces cell surface PD-L1 within 4 h.</cell><cell>1 triggers PD-L1 protein dimerization and</cell><cell>[11]</cell></row><row><cell></cell><cell>cells, human colon</cell><cell></cell><cell>internalization into the nucleus, thereby activating</cell><cell></cell></row><row><cell></cell><cell>cancer cells.</cell><cell></cell><cell>immunosuppression.</cell><cell></cell></row><row><cell>9 (ARB-272572)</cell><cell>No specific cancer</cell><cell>100-500 nM of 9 can significantly reduce cell surface PD-L1 within</cell><cell>9 blocks the PD-1/PD-L1 pathway by triggering PD-</cell><cell>[51]</cell></row><row><cell></cell><cell></cell><cell>1 h.</cell><cell>L1 dimerization and internalization to activate</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>immunity.</cell><cell></cell></row><row><cell>11</cell><cell>Human breast cancer</cell><cell>11 (10 μM) exhibited time-and dose-dependent promotion of PD-L1</cell><cell></cell><cell></cell></row><row><cell></cell><cell>cells</cell><cell>degradation in MDA-MB-231 cells. 11 also achieved a good tumor</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>inhibitory effect at 80 or 160 mg/kg orally in vivo.</cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p>European Journal of Medicinal Chemistry 268 (2024) 116267</p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments</head><p>This research was supported by the <rs type="funder">National Natural Science Foundation of China (NSFC</rs>, grant numbers <rs type="grantNumber">21877101</rs>, <rs type="grantNumber">22177105</rs>), the <rs type="funder">Zhejiang Leading Innovation and Entrepreneurship Team</rs> (grant number <rs type="grantNumber">2018R01015</rs>) and the <rs type="funder">Zhejiang Provincial Key Discipline of Chemical Biology</rs>.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_6evg9fk">
					<idno type="grant-number">21877101</idno>
				</org>
				<org type="funding" xml:id="_G6fRzkp">
					<idno type="grant-number">22177105</idno>
				</org>
				<org type="funding" xml:id="_g8xtP3s">
					<idno type="grant-number">2018R01015</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data availability</head><p>No data was used for the research described in the article.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PD-L1</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations</title>
		<author>
			<persName><forename type="first">W</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1126/scitranslmed.aad7118</idno>
		<ptr target="https://doi.org/10.1126/scitranslmed.aad7118" />
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The blockade of immune checkpoints in cancer immunotherapy</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Pardoll</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrc3239</idno>
		<ptr target="https://doi.org/10.1038/nrc3239" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="252" to="264" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The B7 family revisited</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Greenwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Sharpe</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev.immunol.23.021704.115611</idno>
		<ptr target="https://doi.org/10.1146/annurev.immunol.23.021704.115611" />
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="515" to="548" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Antonia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Villegas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vicente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Murakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yokoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chiappori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Wit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bourhaba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Quantin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tokito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mekhail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Planchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-C</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Karapetis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hiret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ostoros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kubota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Paz-Ares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De Castro Carpeño</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wadsworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Melillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Dennis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Özgüroglu</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1709937</idno>
		<ptr target="https://doi.org/10.1056/NEJMoa1709937" />
	</analytic>
	<monogr>
		<title level="m">Durvalumab after Chemoradiotherapy in stage III non-small-cell lung cancer</title>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="1919" to="1929" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Atezolizumab: first Global approval</title>
		<author>
			<persName><forename type="first">A</forename><surname>Markham</surname></persName>
		</author>
		<idno type="DOI">10.1007/s40265-016-0618-8</idno>
		<ptr target="https://doi.org/10.1007/s40265-016-0618-8" />
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1227" to="1232" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zou</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(20)30365-9</idno>
		<ptr target="https://doi.org/10.1016/S2213-2600(20)30365-9" />
	</analytic>
	<monogr>
		<title level="j">Lancet Respir. Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="305" to="314" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Tislelizumab: first approval</title>
		<author>
			<persName><forename type="first">A</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Keam</surname></persName>
		</author>
		<idno type="DOI">10.1007/s40265-020-01286-z</idno>
		<ptr target="https://doi.org/10.1007/s40265-020-01286-z" />
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="617" to="624" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Immune checkpoint blockade: a common denominator approach to cancer therapy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Topalian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Drake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Pardoll</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ccell.2015.03.001</idno>
		<ptr target="https://doi.org/10.1016/j.ccell.2015.03.001" />
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="450" to="461" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Progress in PD-1/PD-L1 pathway inhibitors: from biomacromolecules to small molecules</title>
		<author>
			<persName><forename type="first">X</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xiang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejmech.2019.111876</idno>
		<ptr target="https://doi.org/10.1016/j.ejmech.2019.111876" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page">111876</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Small molecules drive Big Improvements in Immuno-oncology therapies</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Huck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kötzner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Urbahns</surname></persName>
		</author>
		<idno type="DOI">10.1002/anie.201707816</idno>
		<ptr target="https://doi.org/10.1002/anie.201707816" />
	</analytic>
	<monogr>
		<title level="j">Angew. Chem. Int. Ed. Engl</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="4412" to="4428" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Koblish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rios-Doria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Volgina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zolotarjova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kapilashrami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Behshad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Covington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">O</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Diamond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Soloviev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>O'hayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kanellopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rupar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dimatteo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Thekkat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Geschwindt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Marando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yeleswaram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Scherle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hollis</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-21-1156</idno>
		<ptr target="https://doi.org/10.1158/2159-8290.CD-21-1156" />
	</analytic>
	<monogr>
		<title level="m">Characterization of INCB086550: a potent and novel smallmolecule PD-L1 inhibitor</title>
		<imprint>
			<date type="published" when="2022">2022</date>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1482" to="1499" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Metabolism and interspecies variation of immh-010, a programmed cell death ligand 1 inhibitor prodrug</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sheng</surname></persName>
		</author>
		<idno type="DOI">10.3390/pharmaceutics13050598</idno>
		<ptr target="https://doi.org/10.3390/pharmaceutics13050598" />
	</analytic>
	<monogr>
		<title level="j">Pharmaceutics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Immune checkpoint signaling and cancer immunotherapy</title>
		<author>
			<persName><forename type="first">X</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41422-020-0343-4</idno>
		<ptr target="https://doi.org/10.1038/s41422-020-0343-4" />
	</analytic>
	<monogr>
		<title level="j">Cell Res</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="660" to="669" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Noncytomembrane PD-L1: an atypical target for cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ying</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bai</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.phrs.2021.105741</idno>
		<ptr target="https://doi.org/10.1016/j.phrs.2021.105741" />
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Res</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="page">105741</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Burr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Sparbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Woods</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Beavis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y N</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Bell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stolzenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Gilan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bloor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Noori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Morgens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Bassik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Neeson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Behren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Darcy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S.-J</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Voskoboinik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Trapani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cebon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Dawson</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature23643</idno>
		<ptr target="https://doi.org/10.1038/nature23643" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">549</biblScope>
			<biblScope unit="page" from="101" to="105" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants</title>
		<author>
			<persName><forename type="first">S</forename><surname>Chowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Veyhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jessa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Polyakova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alenzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Macmillan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ralhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Walfish</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.8698</idno>
		<ptr target="https://doi.org/10.18632/oncotarget.8698" />
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="32318" to="32328" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Discovery of Pyrrole-imidazole Polyamides as PD-L1 expression inhibitors and their anticancer activity via immune and Nonimmune pathways</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Narva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sugiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.1c00120</idno>
		<ptr target="https://doi.org/10.1021/acs.jmedchem.1c00120" />
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="6021" to="6036" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1-AKT-mTOR/Bcl2 pathway</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">N</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">M</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Awadasseid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1080/14756366.2023.2230388</idno>
		<ptr target="https://doi.org/10.1080/14756366.2023.2230388" />
	</analytic>
	<monogr>
		<title level="j">J. Enzyme Inhib. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page">2230388</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Mask mitigates MAPT-and FUS-induced degeneration by enhancing autophagy through lysosomal acidification</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1080/15548627.2017.1362524</idno>
		<ptr target="https://doi.org/10.1080/15548627.2017.1362524" />
	</analytic>
	<monogr>
		<title level="j">Autophagy</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1924" to="1938" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The role of ubiquitination and deubiquitination in the regulation of cell junctions</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Culley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13238-017-0486-3</idno>
		<ptr target="https://doi.org/10.1007/s13238-017-0486-3" />
	</analytic>
	<monogr>
		<title level="j">Protein Cell</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="754" to="769" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Damgaard</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41418-020-00703-w</idno>
		<ptr target="https://doi.org/10.1038/s41418-020-00703-w" />
	</analytic>
	<monogr>
		<title level="j">Cell Death Differ</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="423" to="426" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Endoplasmic Reticulum Stress : Molecular Mechanism and Therapeutic Targets</title>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xia</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41392-023-01570-w</idno>
		<ptr target="https://doi.org/10.1038/s41392-023-01570-w" />
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">-Y</forename><surname>Yim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mizushima</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41421-020-0141-7</idno>
		<ptr target="https://doi.org/10.1038/s41421-020-0141-7" />
	</analytic>
	<monogr>
		<title level="m">Lysosome biology in autophagy</title>
		<imprint>
			<date type="published" when="2020">2020</date>
			<biblScope unit="volume">6</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Signals from the lysosome: a control centre for cellular clearance and energy metabolism</title>
		<author>
			<persName><forename type="first">C</forename><surname>Settembre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fraldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Medina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ballabio</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrm3565</idno>
		<ptr target="https://doi.org/10.1038/nrm3565" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Mol. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="283" to="296" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Crosstalk between Mammalian autophagy and the ubiquitin-proteasome system</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Kocaturk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gozuacik</surname></persName>
		</author>
		<idno type="DOI">10.3389/fcell.2018.00128</idno>
		<ptr target="https://doi.org/10.3389/fcell.2018.00128" />
	</analytic>
	<monogr>
		<title level="j">Front. Cell Dev. Biol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">128</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Development of targeted protein degradation therapeutics</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Chamberlain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Hamann</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41589-019-0362-y</idno>
		<ptr target="https://doi.org/10.1038/s41589-019-0362-y" />
	</analytic>
	<monogr>
		<title level="j">Nat. Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="937" to="944" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Prey for the proteasome: targeted protein degradation-A Medicinal Chemist&apos;s perspective</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Luh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Scheib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Juenemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wortmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brands</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Cromm</surname></persName>
		</author>
		<idno type="DOI">10.1002/anie.202004310</idno>
		<ptr target="https://doi.org/10.1002/anie.202004310" />
	</analytic>
	<monogr>
		<title level="j">Angew. Chem. Int. Ed. Engl</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="15448" to="15466" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">New class of molecule targets proteins outside cells for degradation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Whitworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ciulli</surname></persName>
		</author>
		<idno type="DOI">10.1038/d41586-020-02211-w</idno>
		<ptr target="https://doi.org/10.1038/d41586-020-02211-w" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">584</biblScope>
			<biblScope unit="page" from="193" to="194" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">PROTAC targeted protein degraders: the past is prologue</title>
		<author>
			<persName><forename type="first">M</forename><surname>Békés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Langley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Crews</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41573-021-00371-6</idno>
		<idno>41573-021-00371-6</idno>
		<ptr target="https://doi.org/10.1038/s" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Drug Discov</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="181" to="200" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Reversible Spatiotemporal control of induced protein degradation by Bistable PhotoPROTACs</title>
		<author>
			<persName><forename type="first">P</forename><surname>Pfaff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T G</forename><surname>Samarasinghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Crews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Carreira</surname></persName>
		</author>
		<idno type="DOI">10.1021/acscentsci.9b00713</idno>
		<ptr target="https://doi.org/10.1021/acscentsci.9b00713" />
	</analytic>
	<monogr>
		<title level="j">ACS Cent. Sci</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="1682" to="1690" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">AUTACs: Cargo-specific degraders using selective autophagy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moriyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Miki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Akaike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Itto-Nakama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arimoto</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molcel.2019.09.009</idno>
		<ptr target="https://doi.org/10.1016/j.molcel.2019.09.009" />
	</analytic>
	<monogr>
		<title level="j">Mol. Cell</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="797" to="810" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">ATTEC: a potential new approach to target proteinopathies</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lu</surname></persName>
		</author>
		<idno type="DOI">10.1080/15548627.2019.1688556</idno>
		<ptr target="https://doi.org/10.1080/15548627" />
	</analytic>
	<monogr>
		<title level="j">Autophagy</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="185" to="187" />
			<date type="published" when="2019">2020. 2019.1688556</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bourdenx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Martín-Segura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Scrivo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Rodriguez-Navarro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kaushik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tasset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Diaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Storm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">R</forename><surname>Juste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Luengo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Clement</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Krogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mosharov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Santambrogio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Grueninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Collin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Swaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sulzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gavathiotis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Cuervo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cell.2021.03.048</idno>
		<ptr target="https://doi.org/10.1016/j.cell.2021.03.048" />
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="2696" to="2714" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Heo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Na</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Chi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><surname>Kwon</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-022-28520-4</idno>
		<ptr target="https://doi.org/10.1038/s41467-022-28520-4" />
	</analytic>
	<monogr>
		<title level="j">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Discovery of novel resorcinol diphenyl etherbased PROTAC-like molecules as dual inhibitors and degraders of PD-L1</title>
		<author>
			<persName><forename type="first">B</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejmech.2020.112377</idno>
		<ptr target="https://doi.org/10.1016/j.ejmech.2020.112377" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">199</biblScope>
			<biblScope unit="page">112377</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Lysosome-targeting chimaeras for degradation of extracellular proteins</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Banik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pedram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wisnovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Bertozzi</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41586-020-2545-9</idno>
		<ptr target="https://doi.org/10.1038/s41586-020-2545-9" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">584</biblScope>
			<biblScope unit="page" from="291" to="297" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bioorg.2021.104833</idno>
		<ptr target="https://doi.org/10.1016/j.bioorg.2021.104833" />
	</analytic>
	<monogr>
		<title level="j">Bioorg. Chem</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page">104833</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cclet.2022.107762</idno>
		<ptr target="https://doi.org/10.1016/j.cclet.2022.107762" />
	</analytic>
	<monogr>
		<title level="j">Chinese Chem. Lett</title>
		<imprint>
			<biblScope unit="page">107762</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Bifunctional compounds as molecular degraders for integrin-facilitated targeted protein degradation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fang</surname></persName>
		</author>
		<idno type="DOI">10.1021/jacs.2c08367</idno>
		<ptr target="https://doi.org/10.1021/jacs.2c08367" />
	</analytic>
	<monogr>
		<title level="j">J. Am. Chem. Soc</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="21831" to="21836" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">An αv-RGD integrin inhibitor Toolbox: drug Discovery Insight, challenges and opportunities</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J D</forename><surname>Hatley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J F</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Slack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Ludbrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Lukey</surname></persName>
		</author>
		<idno type="DOI">10.1002/anie.201707948</idno>
		<ptr target="https://doi.org/10.1002/anie.201707948" />
	</analytic>
	<monogr>
		<title level="j">Angew. Chem. Int. Ed. Engl</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="3298" to="3321" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">A shortcut to the lysosome: the mannose-6phosphate-independent pathway</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Coutinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Prata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Alves</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ymgme.2012.07.012</idno>
		<ptr target="https://doi.org/10.1016/j.ymgme.2012.07.012" />
	</analytic>
	<monogr>
		<title level="j">Mol. Genet. Metab</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="257" to="266" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Beyond proteolysis-targeting chimeric molecules: Designing Heterobifunctional molecules based on functional effectors</title>
		<author>
			<persName><forename type="first">L</forename><surname>Hua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.2c00316</idno>
		<ptr target="https://doi.org/10.1021/acs.jmedchem.2c00316" />
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="8091" to="8112" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41589-018-0161-x</idno>
		<ptr target="https://doi.org/10.1038/s41589-018-0161-x" />
	</analytic>
	<monogr>
		<title level="j">Nat. Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="42" to="50" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Cotton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gramespacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Seiple</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Wells</surname></persName>
		</author>
		<idno type="DOI">10.1021/jacs.0c10008</idno>
		<ptr target="https://doi.org/10.1021/jacs.0c10008" />
	</analytic>
	<monogr>
		<title level="j">J. Am. Chem. Soc</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="593" to="598" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Roadmap for optimizing and Broadening antibody-based PROTACs for degradation of cell surface proteins</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gramespacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Cotton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W W</forename><surname>Burroughs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Seiple</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Wells</surname></persName>
		</author>
		<idno type="DOI">10.1021/acschembio.2c00185</idno>
		<ptr target="https://doi.org/10.1021/acschembio.2c00185" />
	</analytic>
	<monogr>
		<title level="j">ACS Chem. Biol</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Antibody targeting of E3 ubiquitin ligases for receptor degradation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Marei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T K</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Kee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Penikalapati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dwivedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saenz-Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dorighi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Kschonsak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kljavin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Amin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Mancini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Janezic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Doan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heinlein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Biehs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lehoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Comps-Agrar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Seshasayee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>De Sauvage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grimmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Agard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>De Sousa E Melo</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41586-022-05235-6</idno>
		<ptr target="https://doi.org/10.1038/s41586-022-05235-6" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">610</biblScope>
			<biblScope unit="page" from="182" to="189" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Article ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation Article ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Offringa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Niehrs</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.chembiol.2023.05.010</idno>
		<ptr target="https://doi.org/10.1016/j.chembiol.2023.05.010" />
	</analytic>
	<monogr>
		<title level="j">Cell Chem. Biol</title>
		<imprint>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Covalently engineered nanobody chimeras for targeted membrane protein degradation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1021/jacs.1c08521</idno>
		<ptr target="https://doi.org/10.1021/jacs.1c08521" />
	</analytic>
	<monogr>
		<title level="j">J. Am. Chem. Soc</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="16377" to="16382" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Perillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Khoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Sahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Hortobagyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ccell.2018.01.009</idno>
		<ptr target="https://doi.org/10.1016/j.ccell.2018.01.009" />
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="187" to="201" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Targeted degradation of PD-L1 and activation of the STING pathway by carbon-dot-based PROTACs for cancer immunotherapy</title>
		<author>
			<persName><forename type="first">W</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1002/anie.202218128</idno>
		<ptr target="https://doi.org/10.1002/anie.202218128" />
	</analytic>
	<monogr>
		<title level="j">Angew. Chemie -Int. Ed</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Thi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">H</forename><surname>Carpio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Dorsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Harasym</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Iott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kadhim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Paratala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lakshminarasimhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Suto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rijnbrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sofia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Moore</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-021-21410-1</idno>
		<ptr target="https://doi.org/10.1038/s41467-021-21410-1" />
	</analytic>
	<monogr>
		<title level="j">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Discovery of small-molecule inhibitors of the PD-1/PD-L1 Axis that promote PD-L1 internalization and degradation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.1c01682</idno>
		<ptr target="https://doi.org/10.1021/acs.jmedchem.1c01682" />
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="3879" to="3893" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">Discovery of Novel PD-L1 Inhibitors that Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.3c01534</idno>
		<ptr target="https://doi.org/10.1021/acs.jmedchem.3c01534" />
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Novel small-molecule PD-L1 inhibitor induces PD-L1 internalization and optimizes the immune microenvironment</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Kuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Min</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Pei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.2c01801</idno>
		<ptr target="https://doi.org/10.1021/acs.jmedchem.2c01801" />
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="2064" to="2083" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Azuma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kawahara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hattori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Iwama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Matsumoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Takamori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hoshino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakanishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Okamoto</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mdu242</idno>
		<ptr target="https://doi.org/10.1093/annonc/mdu242" />
	</analytic>
	<monogr>
		<title level="j">Ann. Oncol. Off. J. Eur. Soc. Med. Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1935" to="1940" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: Implication for optional immune targeted therapy for NSCLC patients with EGFR mutation</title>
		<author>
			<persName><forename type="first">N</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1097/JTO.0000000000000500</idno>
		<ptr target="https://doi.org/10.1097/JTO.0000000000000500" />
	</analytic>
	<monogr>
		<title level="j">J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="910" to="923" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Khoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Sahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Allison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Hortobagyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1038/ncomms12632</idno>
		<ptr target="https://doi.org/10.1038/ncomms12632" />
	</analytic>
	<monogr>
		<title level="j">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Lesinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Owonikoko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ramalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Sun</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41388-019-0877-4</idno>
		<ptr target="https://doi.org/10.1038/s41388-019-0877-4" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="6270" to="6282" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Removal of N-linked glycosylation enhances PD-L1 Detection and predicts anti-PD-1/PD-L1 therapeutic efficacy</title>
		<author>
			<persName><forename type="first">H.-H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-N</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C.-H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K.-M</forename><surname>Rau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C.-K</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S.-C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C.-Y</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T.-C</forename><surname>Hsia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S.-F</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S C</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Wistuba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Hortobagyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M.-C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ccell.2019.06.008</idno>
		<ptr target="https://doi.org/10.1016/j.ccell.2019.06.008" />
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="168" to="178" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">N</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12929-020-00670-x</idno>
		<ptr target="https://doi.org/10.1186/s12929-020-00670-x" />
	</analytic>
	<monogr>
		<title level="j">J. Biomed. Sci</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells</title>
		<author>
			<persName><forename type="first">X.-M</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M.-Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L.-L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M.-X</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-J</forename><surname>Lu</surname></persName>
		</author>
		<idno type="DOI">10.1038/aps.2017.123</idno>
		<ptr target="https://doi.org/10.1038/aps.2017.123" />
	</analytic>
	<monogr>
		<title level="j">Acta Pharmacol. Sin</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1512" to="1520" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Membrane-associated RING-CH 8 functions as a novel PD-L1 E3 ligase to mediate PD-L1 degradation induced by EGFR inhibitors</title>
		<author>
			<persName><forename type="first">G</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Vallega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ramalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Owonikoko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Sun</surname></persName>
		</author>
		<idno type="DOI">10.1158/1541-7786.MCR-21-0147</idno>
		<ptr target="https://doi.org/10.1158/1541-7786.MCR-21-0147" />
	</analytic>
	<monogr>
		<title level="j">Mol. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1622" to="1634" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Najafov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ying</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xia</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-021-22467-8</idno>
		<ptr target="https://doi.org/10.1038/s41467-021-22467-8" />
	</analytic>
	<monogr>
		<title level="j">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Firstin-Human phase 1 study of ES-072, an oral mutant-selective EGFR T790M inhibitor, in non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cllc.2020.07.001</idno>
		<ptr target="https://doi.org/10.1016/j.cllc.2020.07.001" />
	</analytic>
	<monogr>
		<title level="j">Clin. Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="509" to="519" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Intratumoral Copper Modulates PD-L1 expression and influences tumor immune evasion</title>
		<author>
			<persName><forename type="first">F</forename><surname>Voli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Valli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kimpton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Saletta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Giorgi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mercatelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R C</forename><surname>Rouaen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ahmed-Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cirillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mayoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Beavis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Trapani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kavallaris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Vittorio</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-20-0471</idno>
		<ptr target="https://doi.org/10.1158/0008-5472.CAN-20-0471" />
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="4129" to="4144" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Metformin promotes antitumor immunity via endoplasmic-reticulumassociated degradation of PD-L1</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hadad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Purdie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Mccoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Litton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Mittendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Moulder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Symmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Piwnica-Worms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Khoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molcel.2018.07.030</idno>
		<ptr target="https://doi.org/10.1016/j.molcel.2018.07.030" />
	</analytic>
	<monogr>
		<title level="j">Mol. Cell</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="606" to="620" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1</title>
		<author>
			<persName><forename type="first">J</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejphar.2019.172541</idno>
		<ptr target="https://doi.org/10.1016/j.ejphar.2019.172541" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">859</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.7150/thno.45777</idno>
		<ptr target="https://doi.org/10.7150/thno.45777" />
	</analytic>
	<monogr>
		<title level="j">Theranostics</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1970" to="1981" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ouyang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-021-25416-7</idno>
		<ptr target="https://doi.org/10.1038/s41467-021-25416-7" />
	</analytic>
	<monogr>
		<title level="j">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Biphenyl-based small molecule inhibitors: novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction</title>
		<author>
			<persName><forename type="first">P</forename><surname>Sasmal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar Babasahib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Prashantha Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Manjunathaiah</forename><surname>Raghavendra</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bmc.2022.117001</idno>
		<ptr target="https://doi.org/10.1016/j.bmc.2022.117001" />
	</analytic>
	<monogr>
		<title level="j">Bioorganic Med. Chem</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page">117001</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Inside PD-1/PD-L1,2 with their inhibitors</title>
		<author>
			<persName><forename type="first">N</forename><surname>Boisgerault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bertrand</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejmech.2023.115465</idno>
		<ptr target="https://doi.org/10.1016/j.ejmech.2023.115465" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">256</biblScope>
			<biblScope unit="page">115465</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Skalniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Zak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Guzik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Magiera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Musielak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pachota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Szelazek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kocik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grudnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tomala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Krzanik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pyrc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dömling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Holak</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.20050</idno>
		<ptr target="https://doi.org/10.18632/oncotarget.20050" />
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="72167" to="72181" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.1080/2162402X.2020.1831153</idno>
		<ptr target="https://doi.org/10.1080/2162402X.2020.1831153" />
	</analytic>
	<monogr>
		<title level="j">OncoImmunology</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Litton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Arun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Hortobagyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-16-3215</idno>
		<ptr target="https://doi.org/10.1158/1078-0432.CCR-16-3215" />
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="3711" to="3720" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Development of PARP and immune-checkpoint inhibitor combinations</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Pilié</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Yap</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-18-2652</idno>
		<ptr target="https://doi.org/10.1158/0008-5472.CAN-18-2652" />
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="6717" to="6725" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Small-molecule poly(ADP-ribose) polymerase and PD-L1 inhibitor conjugates as dual-action anticancer agents</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ofori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Awuah</surname></persName>
		</author>
		<idno type="DOI">10.1021/acsomega.9b01106</idno>
		<ptr target="https://doi.org/10.1021/acsomega.9b01106" />
	</analytic>
	<monogr>
		<title level="j">ACS Omega</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="12584" to="12597" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Deglycosylation of PD-L1 by 2deoxyglucose reverses PARP inhibitor-induced immunosuppression in triplenegative breast cancer</title>
		<author>
			<persName><forename type="first">B</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C.-W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S.-O</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-J</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C.-W</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L.-C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M.-C</forename><surname>Hung</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pubmed/30323975%0A.http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6176188" />
	</analytic>
	<monogr>
		<title level="j">Am. J. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1837" to="1846" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">BB agonism Averts TIL exhaustion and Licenses PD-1 blockade in glioblastoma and other Intracranial cancers</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Woroniecka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Rhodin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dechant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chongsathidkiet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waibl-Polania</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sanchez-Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Fecci</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-19-1068</idno>
		<ptr target="https://doi.org/10.1158/1078-0432.CCR-19-1068" />
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1349" to="1358" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Saccharide analog, 2deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation</title>
		<author>
			<persName><forename type="first">B</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Lim</surname></persName>
		</author>
		<idno type="DOI">10.1002/mc.23170</idno>
		<ptr target="https://doi.org/10.1002/mc.23170" />
	</analytic>
	<monogr>
		<title level="j">Mol. Carcinog</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="691" to="700" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q.-Y</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lv</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.2114851119</idno>
		<ptr target="https://doi.org/10.1073/pnas.2114851119" />
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U. S. A</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<monogr>
		<author>
			<persName><forename type="first">Q</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.2c01347</idno>
		<ptr target="https://doi.org/10.1021/acs.jmedchem.2c01347" />
		<title level="m">Carbohydrate Strengthens the Immunotherapeutic Effect of Small-Molecule PD-L1 Inhibitors</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Receptor-mediated stimulatory effect of oligochitosan in macrophages</title>
		<author>
			<persName><forename type="first">J</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbrc.2004.03.048</idno>
		<ptr target="https://doi.org/10.1016/j.bbrc.2004.03.048" />
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page" from="414" to="420" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">The mannose receptor: from endocytic receptor and biomarker to regulator of (Meta) Inflammation</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J P</forename><surname>Van Der Zande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nitsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schlautmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Guigas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Burgdorf</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2021.765034</idno>
		<ptr target="https://doi.org/10.3389/fimmu.2021.765034" />
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">765034</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Zak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grudnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Guzik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Zieba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Musielak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dömling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Holak</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.8730</idno>
		<ptr target="https://doi.org/10.18632/oncotarget.8730" />
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="30323" to="30335" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">15d-PGJ₂ decreases PGE₂ synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter</title>
		<author>
			<persName><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bcp.2014.07.032</idno>
		<ptr target="https://doi.org/10.1016/j.bcp.2014.07.032" />
	</analytic>
	<monogr>
		<title level="j">Biochem. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="337" to="347" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/ β-catenin signaling pathway</title>
		<author>
			<persName><forename type="first">I</forename><surname>Egashira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Takahashi-Yanaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nishida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Igawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tomooka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tsuzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakabeppu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kitazono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sasaguri</surname></persName>
		</author>
		<idno type="DOI">10.1111/cas.13106</idno>
		<ptr target="https://doi.org/10.1111/cas.13106" />
	</analytic>
	<monogr>
		<title level="j">Cancer Sci</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="108" to="115" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tang</surname></persName>
		</author>
		<idno type="DOI">10.1136/jitc-2020-001377</idno>
		<ptr target="https://doi.org/10.1136/jitc-2020-001377" />
	</analytic>
	<monogr>
		<title level="j">J. Immunother. Cancer</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbrc.2021.05.022</idno>
		<ptr target="https://doi.org/10.1016/j.bbrc.2021.05.022" />
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">561</biblScope>
			<biblScope unit="page" from="187" to="194" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage</title>
		<author>
			<persName><forename type="first">S</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Holvey-Bates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mahen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Willard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Stark</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.2112674118</idno>
		<ptr target="https://doi.org/10.1073/pnas.2112674118" />
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U. S. A</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tranon.2021.101148</idno>
		<ptr target="https://doi.org/10.1016/j.tranon.2021.101148" />
	</analytic>
	<monogr>
		<title level="j">Transl. Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">101148</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1172/JCI154754</idno>
		<ptr target="https://doi.org/10.1172/JCI154754" />
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="1" to="19" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Tumour-associated macrophages as treatment targets in oncology</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Marchesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Malesci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Laghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Allavena</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrclinonc.2016.217</idno>
		<ptr target="https://doi.org/10.1038/nrclinonc.2016.217" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="399" to="416" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Deubiquitination and stabilization of PD-L1 by CSN5</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Sahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Hortobagyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ccell.2016.10.010</idno>
		<ptr target="https://doi.org/10.1016/j.ccell.2016.10.010" />
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="925" to="939" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome</title>
		<author>
			<persName><forename type="first">S</forename><surname>Uhle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Medalia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Waldron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dumdey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Henklein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bech-Otschir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Berse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sperling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Dubiel</surname></persName>
		</author>
		<idno type="DOI">10.1093/emboj/cdg127</idno>
		<ptr target="https://doi.org/10.1093/emboj/cdg127" />
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1302" to="1312" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Macrophagederived CCL5 facilitates immune escape of colorectal cancer cells via the p65/ STAT3-CSN5-PD-L1 pathway</title>
		<author>
			<persName><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Mi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Du</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41418-019-0460-0</idno>
		<ptr target="https://doi.org/10.1038/s41418-019-0460-0" />
	</analytic>
	<monogr>
		<title level="j">Cell Death Differ</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1765" to="1781" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.apsb.2020.06.014</idno>
		<ptr target="https://doi.org/10.1016/j.apsb.2020.06.014" />
	</analytic>
	<monogr>
		<title level="j">Acta Pharm. Sin. B</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="2299" to="2312" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Ruan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Su</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.pan.2021.01.023</idno>
		<ptr target="https://doi.org/10.1016/j.pan.2021.01.023" />
	</analytic>
	<monogr>
		<title level="j">Pancreatology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="630" to="641" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitinproteasome degradation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jnutbio.2022.109186</idno>
		<ptr target="https://doi.org/10.1016/j.jnutbio.2022.109186" />
	</analytic>
	<monogr>
		<title level="j">J. Nutr. Biochem</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page">109186</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">USP7 limits CDK1 activity throughout the cell cycle</title>
		<author>
			<persName><forename type="first">A</forename><surname>Galarreta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Valledor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ubieto-Capella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lafarga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Zarzuela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Muñoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Malumbres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lecona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Fernandez-Capetillo</surname></persName>
		</author>
		<idno type="DOI">10.15252/embj.201899692</idno>
		<ptr target="https://doi.org/10.15252/embj" />
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">99692</biblScope>
			<date type="published" when="2021">2021. 201899692</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Discovery of a potent and selective degrader for USP7</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Pei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.1002/anie.202204395</idno>
		<ptr target="https://doi.org/10.1002/anie.202204395" />
	</analytic>
	<monogr>
		<title level="j">Angew. Chem. Int. Ed. Engl</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page">202204395</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Discovery and characterization of highly potent and selective allosteric USP7 inhibitors</title>
		<author>
			<persName><forename type="first">G</forename><surname>Gavory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>O'dowd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Helm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Flasz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Arkoudis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dossang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cassidy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mcclelland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Odrzywol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Page</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Barker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Miel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Harrison</surname></persName>
		</author>
		<idno type="DOI">10.1038/nchembio.2528</idno>
		<ptr target="https://doi.org/10.1038/nchembio.2528" />
	</analytic>
	<monogr>
		<title level="j">Nat. Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="118" to="125" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">smallmolecule inhibitors interfere with ubiquitin binding</title>
		<author>
			<persName><forename type="first">L</forename><surname>Kategaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Di Lello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rougé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pastor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kleinheinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-P</forename><surname>Upton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Prakash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Heideker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mccleland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Ritorto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Alessi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Bainbridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C M</forename><surname>Kwok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Stiffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Brasher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jaishankar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Hearn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Renslo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Arkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Peale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gnad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Klijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Blackwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Forrest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ndubaku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Beresini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Tsui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schwerdtfeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Blake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Wertz</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature24006</idno>
		<ptr target="https://doi.org/10.1038/nature24006" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="534" to="538" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>USP</note>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">novel drug target in cancer therapy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Suo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphar.2019.00427</idno>
		<ptr target="https://doi.org/10.3389/fphar.2019.00427" />
	</analytic>
	<monogr>
		<title level="j">Front. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">427</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note>USP</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Suo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.apsb.2020.11.005</idno>
		<ptr target="https://doi.org/10.1016/j.apsb.2020.11.005" />
	</analytic>
	<monogr>
		<title level="j">Acta Pharm. Sin. B</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="694" to="707" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">ANXA1 binds and stabilizes EphA2 to promote nasopharyngeal carcinoma growth and metastasis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">P</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Z</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Nie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Q</forename><surname>Xiao</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-20-0560</idno>
		<ptr target="https://doi.org/10.1158/0008-5472.CAN-20-0560" />
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="4386" to="4398" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">A designed peptide targets two types of modifications of p53 with anti-cancer activity</title>
		<author>
			<persName><forename type="first">L</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Bu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-Y</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.chembiol.2018.03.010</idno>
		<ptr target="https://doi.org/10.1016/j.chembiol.2018.03.010" />
	</analytic>
	<monogr>
		<title level="j">Cell Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="761" to="774" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">ANXA1derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Z</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">P</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Q</forename><surname>Xiao</surname></persName>
		</author>
		<idno type="DOI">10.1136/jitc-2022-006345</idno>
		<ptr target="https://doi.org/10.1136/jitc-2022-006345" />
	</analytic>
	<monogr>
		<title level="j">J. Immunother. Cancer</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Kuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1136/jitc-2021-003819</idno>
		<ptr target="https://doi.org/10.1136/jitc-2021-003819" />
	</analytic>
	<monogr>
		<title level="j">J. Immunother. Cancer</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">UBQLN4 is an ATM substrate that stabilizes the anti-apoptotic proteins BCL2A1 and BCL2L10 in mesothelioma</title>
		<author>
			<persName><forename type="first">F</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nie</surname></persName>
		</author>
		<idno type="DOI">10.1002/1878-0261.13058</idno>
		<ptr target="https://doi.org/10.1002/1878-0261.13058" />
	</analytic>
	<monogr>
		<title level="j">Mol. Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="3738" to="3752" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Palmitoylation of proteins in cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Resh</surname></persName>
		</author>
		<idno type="DOI">10.1042/BST20160233</idno>
		<ptr target="https://doi.org/10.1042/BST20160233" />
	</analytic>
	<monogr>
		<title level="j">Biochem. Soc. Trans</title>
		<imprint>
			<biblScope unit="page" from="409" to="416" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-P</forename><surname>Brosseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41551-019-0375-6</idno>
		<ptr target="https://doi.org/10.1038/s41551-019-0375-6" />
	</analytic>
	<monogr>
		<title level="j">Nat. Biomed. Eng</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="306" to="317" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Palmitoylation stabilizes PD-L1 to promote breast tumor growth</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41422-018-0124-5</idno>
		<ptr target="https://doi.org/10.1038/s41422-018-0124-5" />
	</analytic>
	<monogr>
		<title level="j">Cell Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="83" to="86" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Involvement of ZDHHC9 in lung adenocarcinoma: regulation of PD-L1 stability via palmitoylation</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11626-023-00755-5</idno>
		<ptr target="https://doi.org/10.1007/s11626-023-00755-5" />
	</analytic>
	<monogr>
		<title level="j">Vitr. Cell. Dev. Biol. -Anim</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="193" to="203" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1</title>
		<author>
			<persName><forename type="first">N</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Song</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ebiom.2019.01.054</idno>
		<ptr target="https://doi.org/10.1016/j.ebiom.2019.01.054" />
	</analytic>
	<monogr>
		<title level="j">EBioMedicine</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="151" to="162" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Structure-activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway</title>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">X</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Q</forename><surname>Song</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bioorg.2021.105432</idno>
		<ptr target="https://doi.org/10.1016/j.bioorg.2021.105432" />
	</analytic>
	<monogr>
		<title level="j">Bioorg. Chem</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page">105432</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Synthesis and activity evaluation of aloperine derivatives based on PD-L1 tumor immunity</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">X</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Q</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.16438/j.0513-4870.2021-1597</idno>
		<ptr target="https://doi.org/10.16438/j.0513-4870.2021-1597" />
	</analytic>
	<monogr>
		<title level="j">Yaoxue Xuebao</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1085" to="1094" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR</title>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Min</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Kuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.apsb.2021.03.039</idno>
		<ptr target="https://doi.org/10.1016/j.apsb.2021.03.039" />
	</analytic>
	<monogr>
		<title level="j">Acta Pharm. Sin. B</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="3134" to="3149" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity</title>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41388-020-01592-6</idno>
		<ptr target="https://doi.org/10.1038/s41388-020-01592-6" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1128" to="1146" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Calpain-mediated cleavage of Beclin-1 and autophagy deregulation following retinal ischemic injury in vivo</title>
		<author>
			<persName><forename type="first">R</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Berliocchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Adornetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Varano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cavaliere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rotiroti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Morrone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bagetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Corasaniti</surname></persName>
		</author>
		<idno type="DOI">10.1038/cddis.2011.29</idno>
		<ptr target="https://doi.org/10.1038/cddis.2011.29" />
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">144</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Dihydropyridine calcium channel blockers suppress the transcription of PD-L1 by inhibiting the activation of STAT1</title>
		<author>
			<persName><forename type="first">X</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphar.2020.539261</idno>
		<ptr target="https://doi.org/10.3389/fphar.2020.539261" />
	</analytic>
	<monogr>
		<title level="j">Front. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Design, synthesis and biological evaluation of new dihydropyridine derivatives as PD-L1 degraders for enhancing antitumor immunity</title>
		<author>
			<persName><forename type="first">C</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Che</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Dong</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bioorg.2022.105820</idno>
		<ptr target="https://doi.org/10.1016/j.bioorg.2022.105820" />
	</analytic>
	<monogr>
		<title level="j">Bioorg. Chem</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page">105820</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ouyang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sui</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41392-020-0149-3</idno>
		<ptr target="https://doi.org/10.1038/s41392-020-0149-3" />
	</analytic>
	<monogr>
		<title level="j">Signal Transduct. Target. Ther</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">51</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Ri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">X</forename><surname>Piao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">X</forename><surname>Zuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Jin</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jep.2020.113598</idno>
		<ptr target="https://doi.org/10.1016/j.jep.2020.113598" />
	</analytic>
	<monogr>
		<title level="j">J. Ethnopharmacol</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page">113598</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">The Beneficial role of sunitinib in tumor immune Surveillance by regulating tumor PD-L1</title>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Kuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1002/advs.202001596</idno>
		<ptr target="https://doi.org/10.1002/advs.202001596" />
	</analytic>
	<monogr>
		<title level="j">Adv. Sci</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Piva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moriceau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lomeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Damoiseaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kelley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dahlman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Scumpia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sosman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ribas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hugo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lo</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-17-0401</idno>
		<ptr target="https://doi.org/10.1158/2159-8290.CD-17-0401.CD-17" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Enhancing PD-L1 degradation by ITCH during MAPK inhibitor therapy suppresses Acquired resistance</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Lomeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moriceau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wohlschlegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Piva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Lo</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-21-1463</idno>
		<ptr target="https://doi.org/10.1158/2159-8290.CD-21-1463" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1942" to="1959" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T.-P</forename><surname>Su</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cell.2007.08.036</idno>
		<ptr target="https://doi.org/10.1016/j.cell.2007.08.036" />
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="596" to="610" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Schrock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Spino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Longen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Stabler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Marino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Pasternak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1124/mol.113.087809</idno>
		<ptr target="https://doi.org/10.1124/mol.113.087809" />
	</analytic>
	<monogr>
		<title level="j">Mol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="751" to="762" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Small-molecule Sigma1 modulator induces autophagic degradation of PD-L1</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Maher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Longen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Oyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1158/1541-7786.MCR-17-0166</idno>
		<ptr target="https://doi.org/10.1158/1541-7786.MCR-17-0166" />
	</analytic>
	<monogr>
		<title level="j">Mol. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="243" to="255" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">CJ 2: a novel potent Platinum(IV) prodrug enhances chemo-immunotherapy by facilitating PD-L1 degradation in the cytoplasm and cytomembrane</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.2c01719</idno>
		<ptr target="https://doi.org/10.1021/acs.jmedchem.2c01719" />
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="875" to="889" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">BET Bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bengsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Svoronos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Rutkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Bitler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Allegrezza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yokoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kossenkov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Bradner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Conejo-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.celrep.2016.08.032</idno>
		<ptr target="https://doi.org/10.1016/j.celrep.2016.08.032" />
	</analytic>
	<monogr>
		<title level="j">Cell Rep</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="2829" to="2837" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">The role of peroxisome proliferator-activated receptors (PPAR) in immune responses</title>
		<author>
			<persName><forename type="first">A</forename><surname>Christofides</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Konstantinidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Boussiotis</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.metabol.2020.154338</idno>
		<ptr target="https://doi.org/10.1016/j.metabol.2020.154338" />
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page">154338</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">PPARγ inhibited tumor immune escape by inducing PD-L1 autophagic degradation</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Gou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Che</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hou</surname></persName>
		</author>
		<idno type="DOI">10.1111/cas.15818</idno>
		<ptr target="https://doi.org/10.1111/cas.15818" />
	</analytic>
	<monogr>
		<title level="j">Cancer Sci</title>
		<imprint>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">PPARγ agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hussain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hou</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejphar.2023.175749</idno>
		<ptr target="https://doi.org/10.1016/j.ejphar.2023.175749" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">950</biblScope>
			<biblScope unit="page">175749</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Adipose PD-L1 Modulates PD-1/PD-L1 checkpoint blockade immunotherapy efficacy in breast cancer</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Curiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1080/2162402X.2018.1500107</idno>
		<ptr target="https://doi.org/10.1080/2162402X.2018.1500107" />
	</analytic>
	<monogr>
		<title level="j">OncoImmunology</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells</title>
		<author>
			<persName><forename type="first">T</forename><surname>Gutting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hauber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Klapproth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Dobrota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Herweck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Reichling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Helm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Weidner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eckardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Betge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Belle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sticht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boutros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P A</forename><surname>Ebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cerwenka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Burgermeister</surname></persName>
		</author>
		<idno type="DOI">10.1080/2162402X.2021.1906500</idno>
		<ptr target="https://doi.org/10.1080/2162402X.2021" />
	</analytic>
	<monogr>
		<title level="j">OncoImmunology</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2021">2021. 1906500</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Pparγ inhibition boosts efficacy of pd-l1 checkpoint blockade immunotherapy against murine melanoma in a sexually dimorphic manner</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Curiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.7150/ijbs.42966</idno>
		<ptr target="https://doi.org/10.7150/ijbs.42966" />
	</analytic>
	<monogr>
		<title level="j">Int. J. Biol. Sci</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1526" to="1535" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Rigosertib promotes anti-tumor immunity via autophagic degradation of PD-L1 in colorectal cancer cells</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xiao</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.canlet.2023.216422</idno>
		<ptr target="https://doi.org/10.1016/j.canlet.2023.216422" />
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">577</biblScope>
			<biblScope unit="page">216422</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Mechanisms controlling PD-L1 expression in cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molcel.2019.09.030</idno>
		<ptr target="https://doi.org/10.1016/j.molcel.2019.09.030" />
	</analytic>
	<monogr>
		<title level="j">Mol. Cell</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="359" to="370" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Regulation of PD-L1: emerging routes for targeting tumor immune evasion</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphar.2018.00536</idno>
		<ptr target="https://doi.org/10.3389/fphar.2018.00536" />
	</analytic>
	<monogr>
		<title level="j">Front. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">PD-L1 degradation pathway and immunotherapy for cancer</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Gou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hou</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41419-020-03140-2</idno>
		<ptr target="https://doi.org/10.1038/s41419-020-03140-2" />
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Inhibition of GFAT1 in lung cancer cells destabilizes PD-L1 protein</title>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Saxton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tessema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Belinsky</surname></persName>
		</author>
		<idno type="DOI">10.1093/carcin/bgab063</idno>
		<ptr target="https://doi.org/10.1093/carcin/bgab063" />
	</analytic>
	<monogr>
		<title level="j">Carcinogenesis</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1171" to="1178" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway</title>
		<author>
			<persName><forename type="first">C</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12916-021-02161-8</idno>
		<ptr target="https://doi.org/10.1186/s12916-021-02161-8" />
	</analytic>
	<monogr>
		<title level="j">BMC Med</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Phosphorylated RB promotes cancer immunity by inhibiting NF-κB activation and PD-L1 expression</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Rodrigues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kohli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jimenez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Goodrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molcel.2018.10.034</idno>
		<ptr target="https://doi.org/10.1016/j.molcel.2018.10.034" />
	</analytic>
	<monogr>
		<title level="j">Mol. Cell</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="22" to="35" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">PD-L1 expression is regulated by NF-κB during EMT signaling in gastric carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R.-Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gong</surname></persName>
		</author>
		<idno type="DOI">10.2147/OTT.S224053</idno>
		<ptr target="https://doi.org/10.2147/OTT.S224053" />
	</analytic>
	<monogr>
		<title level="j">OncoTargets Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="10099" to="10105" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">A bis-indolederived NR4A1 antagonist induces PD-L1 degradation and enhances antitumor immunity</title>
		<author>
			<persName><forename type="first">K</forename><surname>Karki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mohankumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">H</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Safe</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-19-2314</idno>
		<ptr target="https://doi.org/10.1158/0008-5472.CAN-19-2314" />
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="1011" to="1023" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cao</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12967-023-04135-1</idno>
		<ptr target="https://doi.org/10.1186/s12967-023-04135-1" />
	</analytic>
	<monogr>
		<title level="j">J. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">341</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Inhibition of immunosuppressive tumors by polymer-Assisted Inductions of immunogenic cell death and Multivalent PD-L1 Crosslinking</title>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Radford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Janát-Amsbury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kopeček</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1002/adfm.201908961</idno>
		<ptr target="https://doi.org/10.1002/adfm.201908961" />
	</analytic>
	<monogr>
		<title level="j">Adv. Funct. Mater</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemoimmunotherapy against carcinoma</title>
		<author>
			<persName><forename type="first">X</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12951-023-01950-y</idno>
		<ptr target="https://doi.org/10.1186/s12951-023-01950-y" />
	</analytic>
	<monogr>
		<title level="j">J. Nanobiotechnology</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Selective degradation of PD-L1 in cancer cells by enzyme-Instructed self-Assembly</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1002/adfm.202102505</idno>
		<ptr target="https://doi.org/10.1002/adfm.202102505" />
	</analytic>
	<monogr>
		<title level="j">Adv. Funct. Mater</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Triptolide inhibits interferon-γ-induced programmed death-1ligand 1 surface expression in breast cancer cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.canlet.2008.05.025</idno>
		<ptr target="https://doi.org/10.1016/j.canlet.2008.05.025" />
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="page" from="337" to="341" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<author>
			<persName><forename type="first">R</forename><surname>Mezzadra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Jae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gomez-Eerland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E W</forename><surname>Logtenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Slagter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Rozeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hofland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Broeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Horlings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F A</forename><surname>Wessels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Blank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J R</forename><surname>Heck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Borst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Brummelkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N M</forename><surname>Schumacher</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature23669</idno>
		<ptr target="https://doi.org/10.1038/nature23669" />
	</analytic>
	<monogr>
		<title level="m">Identification of CMTM6 and CMTM4 as PD-L1 protein regulators</title>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="volume">549</biblScope>
			<biblScope unit="page" from="106" to="110" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">Chemokine-like factor-like MARVEL transmembrane domain containing 6: bioinformatics and experiments in vitro analyze in glioblastoma multiforme</title>
		<author>
			<persName><forename type="first">H</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qu</surname></persName>
		</author>
		<idno type="DOI">10.3389/fnmol.2022.1026927</idno>
		<ptr target="https://doi.org/10.3389/fnmol.2022.1026927" />
	</analytic>
	<monogr>
		<title level="j">Front. Mol. Neurosci</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">1026927</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Gohara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tomonobu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kinoshita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Futami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Audebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L G Y</forename><surname>Komalasari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yoshizawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Murata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K.-I</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kumon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sakaguchi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00109-023-02292-w</idno>
		<ptr target="https://doi.org/10.1007/s00109-023-02292-w" />
	</analytic>
	<monogr>
		<title level="j">J. Mol. Med. (Berl)</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="431" to="447" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade</title>
		<author>
			<persName><forename type="first">X</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M.-C</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molcel.2021.03.037</idno>
		<ptr target="https://doi.org/10.1016/j.molcel.2021.03.037" />
	</analytic>
	<monogr>
		<title level="j">Mol. Cell</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="2317" to="2331" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">ZG16 promotes T-cell mediated immunity through direct binding to PD-L1 in colon cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s40364-022-00396-y</idno>
		<ptr target="https://doi.org/10.1186/s40364-022-00396-y" />
	</analytic>
	<monogr>
		<title level="j">Biomark. Res</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Shang</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2023.1123244</idno>
		<ptr target="https://doi.org/10.3389/fimmu.2023.1123244" />
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.gendis.2022.01.002</idno>
		<ptr target="https://doi.org/10.1016/j.gendis.2022.01.002" />
	</analytic>
	<monogr>
		<title level="j">Genes Dis</title>
		<imprint>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12964-020-00612-y</idno>
		<ptr target="https://doi.org/10.1186/s12964-020-00612-y" />
	</analytic>
	<monogr>
		<title level="j">Cell Commun. Signal</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">112</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Cai</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41419-022-05375-7</idno>
		<ptr target="https://doi.org/10.1038/s41419-022-05375-7" />
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Regulation of PD-L1 expression in the tumor microenvironment</title>
		<author>
			<persName><forename type="first">M</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13045-020-01027-5</idno>
		<idno>13045-020-01027-5</idno>
		<ptr target="https://doi.org/10.1186/s" />
	</analytic>
	<monogr>
		<title level="j">J. Hematol. Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
